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ABSTRACT 
 
ELIZABETH PEMPE CHAPPELL: Characterization of heparan sulfate-protein interactions 
for synthetic heparin design 
(Under the direction of Jian Liu, Ph.D.) 
 
 
Heparin is a widely prescribed anticoagulant that has been in clinical use for over 70 
years. It is a natural product and a special form of heparan sulfate, a heterogeneous 
polysaccharide that is expressed as a proteoglycan on the surface of all animal tissues. In 
recent years, the development of a chemoenzymatic method to synthesize specific heparan 
sulfate polysaccharides and oligosaccharides has enabled studies of the structure-based 
interactions between negatively charged heparan sulfate and its protein binding partners.  
A synthetic version of heparin and its low-molecular-weight derivatives could have 
several advantages over the drugs that are currently available. First, a synthetic drug would 
evade the historically contaminated porcine intestine supply chain from which heparin is 
currently derived. In addition, the structure of the drug could be tailored for improved safety 
and efficacy and to meet the needs of different patient populations. In this dissertation, we 
sought to characterize structure-function relationships of heparan sulfate with several goals: 
to reduce binding to platelet factor 4, an initiating step in heparin-induced thrombocytopenia; 
to identify the structure required for binding to Stabilin receptors, which clear heparins via 
the liver rather than the kidneys; and to create a heparan sulfate structure that has optimum 
bioavailability and activity against factors of the coagulation cascade. Through biochemical, 
cell-based and in vivo assays, we determined that PF4 binding was decreased by Sulf-2 
treatment and by limiting the oligosaccharide length, that a 3-O-sulfated 10-mer is required 
for robust Stabilin binding, that a 19-mer will confer anti-IIa activity and that oligosaccharides 
as short as a 6-mer are bioavailable through subcutaneous injection.  
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CHAPTER I 
INTRODUCTION 
 
Heparan sulfate  
Heparan sulfate (HS) is a widely expressed carbohydrate. As the body’s most 
negatively charged molecule, it interacts with numerous proteins to regulate many biological 
functions relevant to human health and disease. These functions range from embryonic 
development and coagulation to inflammation and cancer metastasis. Heparan sulfate is 
part of the glycosaminoglycan family, the members of which contain long unbranched 
carbohydrates made up of repeating disaccharide units. Other members include keratan 
sulfate, dermatan sulfate, hyaluronan and chondroitin sulfate [1]. 
 
Heparan sulfate structure 
The bioactivity of HS is dependent on its structure, namely the location of 
electronegative sulfo groups along its backbone and the presence of iduronic acid (IdoA), 
glucuronic acid (GlcA) and glucosamine (GlcN) residues (Fig. 1.1). HS exists on the surface 
of animal cells and within the extracellular matrix as a proteoglycan consisting of long 
carbohydrate chains attached to a core protein. Cell surface HS proteoglycans include 
syndecans and glypicans; perlecan and agrin are the primary extracellular examples [2-4]. 
The HS chains are composed of repeating disaccharide units of uronic acid and 
glucosamine. The uronic acid is present as either glucuronic or iduronic acid and can be 
sulfated at the -OH on carbon 2 (2-O-sulfation). The glucosamine can be 6-O- and 3-O-
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sulfated, and its amine group can be acetylated, sulfated or unsubstituted (Fig. 1.1). The 
biological functions of HS proteoglycans are dominated by the HS side chains. 
 
 
 
Figure 1.1. Chemical structure of the disaccharides present in HS. GlcA, glucuronic acid; IdoA, 
iduronic acid; GlcN, glucosamine.  
 
 
 
This broad structural variation in the location of negative groups, in addition to 
variation in length and glycosidic bond position, allows HS to interact with different binding 
protein partners to display many biological functions. Although nonspecific ionic interactions 
between HS and proteins exist, the binding of HS to proteins can be specific. Thus, the 
preparation of unique HS chains with defined sulfation patterns and length is highly 
desirable, as they allow researchers to investigate the substrate specificity of HS-protein 
interactions and provide numerous therapeutic opportunities.   
 
HS biosynthetic enzymes 
HS biosynthesis occurs in the Golgi apparatus and is carried out by a series of 
enzymes (Figure 1.2). The synthesis of HS has two main components: chain elongation and 
modification of the individual sugars. In vivo, the HS chain is elongated by the Exostosin 
genes, Ext1 and Ext2 [5]. This process can be mimicked in vitro by two bacterial 
glycosyltransferases: N-acetylglucosaminyl transferase from the E. coli K5 strain, known as  
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Figure 1.2. Enzyme reactions in the synthesis of heparan sulfate. N-deacetylase/N-sulfotransferase 
replaces N-acetyl groups with N-sulfo groups. C5-epimerase converts glucuronic acid to iduronic acid. 
2-O-, 6-O- and 3-O-sulfotransferase add sulfation at their respective positions. 
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KfiA [6], and heparosan synthase-2 from Pasteurella multocida, or pmHS2 [7]. In laboratory 
syntheses, KfiA and pmHS2 are incubated with uridine 5’-diphospho-N-
trifluoroacetylglucosamine (UDP-NTFA) and UDP-GlcA, respectively; with each cycle of 
incubation, the oligosaccharide is elongated by one sugar unit [8]. GlcNTFA is used 
because it is easily chemically deacetylated to GlcNH2 for later N-sulfation.  
The N-deacetylase/N-sulfotransferase (NDST) enzyme is the first to modify an intact 
HS chain during biosynthesis, and its action is believed to direct the location of all 
subsequent sulfation reactions [9]. The 325-aa C-terminal region (constituting the N-
sulfotransferase domain) of NDST is commonly expressed and used for HS synthesis in 
vitro following chemical deacetylation [10], although recent studies have focused on 
expression of the entire NDST enzyme [11]. Sulfation reactions are carried out by incubating 
HS with a sulfotransferase and 3’-phosphoadenosine 5’-phosphosulfate (PAPS), a natural 
sulfate donor. 
Characterization of NDST-1 by Sheng et al. uncovered a unique substrate specificity 
for this enzyme [12]. Treatment of a synthetic dodecasaccharide substrate with NDST-1 
produced a variety of N-sulfated products containing clusters of GlcNS, suggesting that 
NDST-1 binds to HS at a random position, converts consecutive GlcNAc to GlcNS from the 
non-reducing to reducing end, then releases the substrate when it is five sugars away from 
the reducing end. There are a total of four isoforms of NDST; NDST-2, which is highly 
expressed in mast cells, is proposed to be involved in the synthesis of highly-sulfated 
heparin but not HS [13]. This was principally confirmed by the absence of heparin in mast 
cells from NDST-2 knockout mice [14]. The N-deacetylase and N-sulfotransferase activities 
of NDST-2 through -4 have been investigated, but their use in HS synthesis specifically has 
not been fully explored [15]. 
After N-sulfation, C5-epimerase (C5-epi) converts some D-glucuronic acid residues to 
L-iduronic acid by altering the configuration of carbon 5 [16]. C5-epimerase was recently 
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shown to exhibit a biphasic catalytic mode: depending on the substitution groups of the 
surrounding saccharide residues, the epimerization reaction is either reversible or 
irreversible. Using structurally defined oligosaccharides, Sheng et al. identified that C5-epi 
will act on a GlcA residue if the residue immediately upstream (towards the non-reducing 
end) is a GlcNS residue. If the residue three sugars upstream is GlcNS, GlcNH2 or not 
present, the reaction is reversible; if it is GlcNAc, the reaction is irreversible (Figure 1.3A) 
[17]. This finding will enable researchers to “lock” IdoA sugars in place and synthesize pure 
HS oligosaccharides containing IdoA during in vitro synthesis.  
A series of O-sulfotransferases then sulfate their respective positions on HS. 
Heparan sulfate 2-O-sulfotransferase (2-OST) catalyzes the transfer of an -OSO3H group 
from PAPS to IdoA or GlcA. It is present in one isoform and has approximately five-fold 
greater affinity for IdoA than for GlcA [18], although mutational analyses have suggested 
that the preference for IdoA over GlcA can be controlled through site-specific mutations [19].  
6-OST sulfates both GlcNAc and GlcNS to form GlcNAc6S and GlcNS6S, 
respectively. 6-OST isoforms, of which there are three, appear to sulfate the same 
substrates [20]; however, placement of 6-O-sulfo groups in oligosaccharides can be 
controlled somewhat by the enzymatic reaction time and by elongating oligosaccharides 
already containing 6-O-sulfated glucosamine [21]. A combination of 6-OST-1 and -3 was 
demonstrated to prefer GlcNAc residues close to the reducing end of oligosaccharide 
substrates, but placement of a single 6-O-sulfo group in an oligosaccharide remains a 
challenge [21, 22].  
3-OST adds a sulfo group to the 3-OH position of GlcN residues and is present in 
seven isoforms. In endogenous HS, 3-O-sulfation is a relatively rare modification, sulfating 
only a small component of disaccharides [23]. However, the presence of 3-O-sulfation is 
critical for multiple types of HS activity, including binding to antithrombin, gD (a herpes 
simplex virus type 1 entry receptor) and Stabilin-1/2 (heparin clearance receptors) [24, 25].   
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Figure 1.3. Substrate recognition of C5-epimerase and 3OST. A. The epimerization reaction of C5-epi 
is reversible or irreversible depending on the GlcN three sugars towards the nonreducing end of the 
glucuronic acid to be modified. The asterisk indicates a GlcA that could be epimerized if the sugar to 
the immediate left is GlcNS. B. Substrates of the seven 3OST isoforms. The position that will carry 
the 3-O-sulfo group is shown in blue. 
 
 
 
The 3-OST isoforms exhibit greater than 60% homology in their sulfotransferase 
domains [9], and the substrate recognition of the 3-OSTs generally falls into one of three 
types, depending on the sugar linked to the non-reducing side of the glucosamine to be 
modified. 3-OST-1 will transfer a sulfo group to a GlcNS that is linked to a GlcA or IdoA at 
the non-reducing end. 3-OST-5 sulfates a GlcNS that is linked to an IdoA2S, GlcA or IdoA. 
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The remaining 3OSTs (-2, -3A, -3B, -4 and -6) will sulfate a GlcNS or GlcNH2 linked to an 
IdoA2S at the non-reducing end (Figure 1.3B). These different substrate specificities allow 
placement of 3-O-sulfo groups in specific locations depending on the identity of the 
neighboring residue. Based on their ease of production in E. coli, 3-OST-1, -3 and -5 are 
most commonly used in chemoenzymatic syntheses; 3-OST-3 and -5 will produce HS that 
binds to gD [24]. A complete list of the enzymes used in HS synthesis is given in Table 1.1.  
 
Heparin vs. HS 
Heparin and HS have very similar structures; however, heparin refers to a special 
form of HS that has more sulfo groups and a higher level of iduronic acid residues. Heparan 
sulfate is produced by virtually all cells in species ranging from simple invertebrates to 
humans [23]. Heparin, on the other hand, is produced by mast cells and is present only in 
some tissues of select members of the animal kingdom. Interesting examples include the 
observations that rabbit tissues do not contain heparin [26] and that chicken skin contains 
relatively high levels of heparin [27].  
 Heparan sulfate proteoglycans appeared early in metazoan evolution, and their 
common structural motifs are conserved in modern organisms [23]. Uncharacterized 
proteoglycans have been identified in ancient multicellular organisms such as Hydra [28], 
and lower organisms such as Drosophila and C. elegans contain homologs of syndecan, 
glypican and perlecan [29]. The essential role of HS proteoglycans (and heparins) in the 
development and physiology of living organisms is supported by their prevalence throughout 
the animal kingdom.  
Heparan sulfate is commonly made up of two domains, one composed of N-
acetylated and N-sulfated disaccharides containing glucuronic acid and one composed of 
more highly sulfated disaccharides containing iduronic acid [26]. Mammalian heparan  
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Enzymes Abbreviated 
Names 
Enzymatic function Expression 
system 
N-deacetylase/N-
sulfotransferase -1 
NDST-1 Converts a GlcNAc to a GlcNS residue E. coli ([30]),  
S. cerevisiae 
([11]) 
N-deacetylase/N-
sulfotransferase -2 
NDST-2 Similar to NDST-1, but prone to synthesize a 
long cluster of GlcA-GlcNS repeating domains 
E. coli ([31]), 
insect cells ([32]) 
N-deacetylase/N-
sulfotransferase -3 
NDST-3 Similar to NDST-1  
N-deacetylase/N-
sulfotransferase -4 
NDST-4 Similar to NDST-1  
N-sulfotransferase
1
 NST Converts a GlcNH2 to a GlcNS residue E. coli ([30]),  
K. lactis ([33]) 
C5-epimerase C5-epi Converts a GlcA to an IdoA residue E. coli ([34]),  
insect cells ([35]) 
2-O-sulfotransferase 2-OST Introduces a sulfo group to the 2-OH position of 
an IdoA or a GlcA residue 
E. coli ([36]),  
K. lactis ([33]), 
insect cells ([32]) 
6-O-sulfotransferase 1 6-OST-1 Introduces a sulfo group to the 6-OH position of a 
GlcNS or a GlcNAc residue 
E. coli ([36]),  
K. lactis ([33]), 
insect cells ([32]) 
6-O-sulfotransferase 2 6-OST-2 Same as 6-OST-1 insect cells ([32]) 
6-O-sulfotransferase 3 6-OST-3 Same as 6-OST-1 E. coli ([37]),  
K. lactis ([33]) 
3-O-sulfotransferase 1 3-OST-1 Introduces a sulfo group to the 3-OH position of a 
GlcNS±6S residue that is linked to a GlcA (or an 
IdoA) on the nonreducing end 
E. coli ([38]),  
K. lactis ([33]), 
insect cells ([39]) 
3-O-sulfotransferase 2 3-OST-2 Introduces a sulfo group to the 3-OH position of a 
GlcNS±6S residue that is linked to an IdoA2S on 
the nonreducing end 
insect cells ([40]) 
3-O-sulfotransferase 
3A 
3-OST-3A Introduces a sulfo group to the 3-OH position of a 
GlcNS±6S residue that is linked to an IdoA2S on 
the nonreducing end 
E. coli ([41]),  
insect cells ([42]) 
3-O-sulfotransferase 
3B 
3-OST-3B Same as 3-OST-3A insect cells ([40]) 
3-O-sulfotransferase 4 3-OST-4 Same as 3-OST-3A insect cells ([40]) 
3-O-sulfotransferase 5 3-OST-5 Has both 3-OST-1 and 3-OST-3A substrate 
specificities 
E. coli ([43]),  
insect cells ([44]) 
3-O-sulfotransferase 6 3-OST-6 Same as 3-OST-3A  
pmHS2
A
 from  
P. multocida 
Transfers a GlcA and a GlcNAc (or a GlcNTFA) 
residue to the backbone 
E. coli ([7]) 
KfiA
B
 from  
E. coli 
Transfers a GlcNAc (or a GlcNTFA) residue to 
the backbone 
E. coli ([6]) 
a
 N-sulfotransferase is a protein that is composed of the N-sulfotransferase domain of NDST-1. NST 
is an unnatural protein, and it is used in the chemoenzymatic synthesis to convert a GlcNH2 residue 
to a GlcNS residue. 
b
 Both pmHS2 and KfiA are bacteria enzymes, not HS biosynthetic enzymes. However, they are used 
for building the backbone structure of HS during chemoenzymatic synthesis. 
 
Table 1.1. List of HS biosynthetic enzymes.  
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sulfates from many different sources have been found to contain these domains in addition 
to a short linker that is positioned between the domains [45]. Heparan sulfate is ubiquitous in 
invertebrates as well; a survey of 23 invertebrates from 13 different phyla identified heparan 
sulfate in all of the species studied [46]. Studies in crustaceans and mollusks have 
characterized heparan sulfate in various tissues and found that the concentration of heparan 
sulfate is directly proportional to the salinity of the habitat [26].  
 There is much greater variation in the distribution of heparin, both among different 
organisms and within the tissues of a given species. In mammals, heparin is generally found 
in tissues that are in direct contact with the external environment, such as the skin, 
intestines and lungs, but it has low prevalence in the brain, muscle and kidneys of most 
species [26]. Several mollusks have been shown to contain heparin-like polysaccharides 
that possess anticoagulant activity [47, 48], but heparin is not present in all invertebrates. 
Like HS, heparin is understood to be comprised primarily of two different regions: a highly 
sulfated region that is subject to degradation by heparinase and a lowly sulfated region that 
is susceptible to heparitinase II, and the length and quantities of these regions depend on 
the species of origin and the specific tissue [26]. For example, bovine lung heparin is rich in 
the heparinase-cleavable region, while bovine intestinal heparin and mollusk heparins 
contain more of the heparitinase II-cleavable region [49, 50]. The roles of heparan sulfate 
and heparin appear to be the same in vertebrates and invertebrates. 
 
Current anticoagulant therapies 
 Anticoagulants prevent the formation of blood clots by interfering with the blood 
coagulation cascade. Commonly used anticoagulants include vitamin K antagonists, 
thrombin inhibitors (both direct and indirect) and factor Xa inhibitors. Heparin drugs function 
as indirect (antithrombin-mediated) thrombin and Xa inhibitors, and they are typically 
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classified as unfractionated heparin, low-molecular-weight heparin or synthetic 
pentasaccharides. 
 Warfarin, the primary vitamin K antagonist, is a synthetic derivative of a natural 
product of plant and fungal origin, dicumarol [51]. It functions by inhibiting the biosynthesis 
of vitamin K-dependent procoagulant factors II (also called prothrombin), VII, IX and X [52]. 
It is given orally, and due to the long half-lives of some of these factors, it can take several 
days for it to reach its full antithrombotic effect. Warfarin is a mixture of R and S enantiomers 
(which are both active, but to different degrees) [53], and it is influenced by drug interactions 
and diet, especially the intake of vitamin K-rich greens. Thus, warfarin drugs require close 
monitoring and can cause bleeding complications [52]. Available reversal agents include 
vitamin K, fresh frozen plasma and bypassing agents such as prothrombin complex 
concentrates or recombinant factor VIIa. Warfarin is most typically administered for 
thrombosis treatment or prophylaxis.  
 Full-length unfractionated heparin (UFH) is isolated as a mixture from animal mast 
cells, primarily porcine intestine. It was discovered in 1916, before the establishment of the 
Food and Drug Administration, and it is one of the oldest drugs still in clinical use [54]. 
Heparin is a potent activator of antithrombin, a protein that inhibits factors Xa and IIa to 
prevent the downstream formation of fibrin clots (Fig. 1.4). Its inexpensive production, short 
half-life and reversibility with protamine make UFH an advantageous drug for surgery and 
for handling blood in laboratory settings. It also has certain drawbacks, including an 
unreliable supply chain, side effects such as heparin-induced thrombocyptopenia (HIT) and 
dosing difficulties due to its heterogeneous nature. Its short (30- to 60-min) half-life and 
intravenous administration route limit its clinical use to in-patient procedures, and it must be 
monitored using activated partial thromboplastin time [52].  
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Figure 1.4. Interaction of anticoagulant drugs with the coagulation cascade. Coagulation is initiated 
by the intrinsic or extrinsic pathway. The two pathways converge on the activation of factor X to Xa 
and result in the formation of fibrin clots. Target sites for current anticoagulant drugs are shown in 
red. 
 
  
 Low-molecular-weight heparin (LMWH) drugs, such as enoxaparin (Lovenox), are a 
mixture of products from depolymerized UFH. The average length is about 15 saccharide 
units, compared to 40 for UFH. LMWH inhibits IIa to a lesser extent than UFH, as not all 
components of the mixture are long enough to form an antithrombin:Xa:IIa complex. It tends 
to be safer than UFH, having a lower incidence of HIT, and its longer half-life and 
subcutaneous dosing make it more appropriate for venous thromboembolism prophylaxis 
and treatment. Its more predictable anticoagulant effect also means that fixed or weight-
based dosing is possible without routine laboratory monitoring [52]. At least a fraction of 
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LMWH is cleared by the kidneys, so anti-Xa monitoring is recommended for patients with 
renal impairment as well as for elderly, pregnant or obese patients.  
 The shortest and most recently developed heparin drugs, such as fondaparinux 
(Arixtra), are analogs of the antithrombin-binding heparin pentasaccharide. They inhibit Xa 
and do not have anti-IIa activity. Arixtra is produced through a lengthy chemical synthesis 
and, unlike UFH and LWMH, it is a pure compound, not a mixture. Like LMWH, it is dosed 
subcutaneously. Arixtra has a half-life of approximately 17 hours, allows for unmonitored 
once-daily dosing and is currently approved for deep vein thrombosis and pulmonary 
embolism [55]. A hypermethylated version of fondaparinux known as idraparinux was 
developed in the late 1990s [56]. It has a 30-fold higher affinity for antithrombin than Arixtra, 
and its 120-hour half-life permits once-weekly administration [55]. Like Arixtra, it does not 
have an antidote. However, a biotinylated version of idraparinux was developed, and its anti-
Xa activity is effectively reversed by avidin [57]. Both fondaparinux and idraparinux do not 
bind to PF4 and do not show evidence of causing heparin-induced thrombocytopenia. 
Despite these promising developments, idraparinux was associated with an increased risk of 
major hemorrhage in clinical trials [58], and it was withdrawn from further development. 
 Thrombin, or factor IIa, is a serine protease that is central to hemostasis. Direct 
thrombin inhibitors function independently of antithrombin and do not bind PF4 [52]. The 
drugs lepirudin, desirudin and bivalirudin are derivatives of hirudin, a naturally occurring 
peptide found in the salivary glands of medicinal leeches, and they are approved for 
thrombosis with HIT, postsurgical VTE and unstable angina, respectively [52]. Argatroban is 
a reversible small-molecule direct thrombin binder that is also approved for HIT. Dabigatran 
(given as an oral prodrug, dabigatran etexilate), is a small-molecule competitive direct 
thrombin inhibitor that is approved for deep vein thrombosis [52]. It was shown to be equal 
to enoxaparin in terms of safety and efficacy in reducing DVT after hip replacement surgery 
[59].  
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 Direct Xa inhibitors have the advantage of bypassing intermediary molecules like 
antithrombin, which may result in more consistent anticoagulation. Razaxaban and apixaban 
are both oral small-molecule direct Xa inhibitors developed by Bristol-Myers Squibb. 
Razaxaban was abandoned in favor of apixaban due to its better safety profile, and 
apixaban (Eliquis) was FDA-approved in December 2012. Rivaroxaban is another FDA-
approved Xa inhibitor; it is also a small molecule developed by Bayer that can be given in 
once-daily oral doses. Of all oral anticoagulants, rivaroxaban has been evaluated the most 
extensively and in largest patient populations [55]. It has a half-life that is considerably 
shorter than other oral Xa inhibitors (about 5 to 9 hours) [52], and it has a low risk of drug-
drug interactions [60]. Although they have many promising characteristics, a disadvantage 
of the oral Xa inhibitors is their lack of a reversal agent.    
 Selective direct inhibitors of factors IXa and XIa are also in development, but they 
have yet to complete clinical trials [55].  
 
Strategies for improved heparin drugs 
 Although unfractionated, low-molecular-weight and pentasaccharide heparin drugs 
are presently available, there is a need for more advanced heparins that suit the 
requirements of distinct patient populations. As long as binding to antithrombin is 
maintained, the structure of heparin can be rationally designed to allow for optimal 
interactions with other molecules and desirable pharmacological properties.  
A primary consideration in the administration of a drug is its bioavailability and 
delivery route, and the ease of administration is a major factor in patient compliance and 
acceptability. An oral heparin would be an improved anticoagulant for long-term therapy, 
such as the prevention of thrombosis [61], but its high molecular weight and negative charge 
density limit its oral bioavailability [62]. Several efforts have been made to synthesize orally 
available heparins. To counteract the poor delivery of anionic heparin across the mucosal 
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gastrointestinal lining, penetration enhancers such as SNAC (sodium N-[8-(2-
hydroxybenzoyl)amino]caprylate) have been administered with heparin, with promising 
results [63]. Other approaches include novel drug delivery systems, such as nanoparticles, 
lipid conjugates and enteric coatings [64-66]. Despite experimental successes, no oral 
heparin formulations have reached the market. A more relevant issue for rational synthesis 
of the heparin carbohydrate chain would be to focus on structures that were bioavailable via 
subcutaneous injection (like Arixtra and LMWHs) rather than intravenously. Although 
unfractionated heparin can be administered subcutaneously, its bioavailability is reduced to 
about 30% (compared to nearly 100% for LMWH), so much higher doses are required [67, 
68]. Thus, heparins of reduced molecular weight are likely to have high subcutaneous 
bioavailability.  
After administration, side effects of heparin drugs come into consideration. For many 
drugs, unwanted side effects can be avoided by modifying the structure of the active 
compound, but the heterogeneous nature of the heparin polysaccharide chain negates this 
approach, even when dealing with fragmented low-molecular-weight heparins [69]. Bleeding 
is the most common side effect of heparin therapy; major bleeding occurs in 4 to 5% of 
patients receiving unfractionated heparin [70, 71]. Other complications include heparin-
induced thrombocytopenia and, less commonly, osteoporosis, eosinophilia, skin reactions, 
alopecia (hair loss), liver dysfunction and hyperkalemia (elevated blood potassium) [72]. 
There is also an acute anaphylactic reaction that occurs within 5 to 10 minutes after 
commencing intravenous heparin bolus therapy; it includes the abrupt onset of chills and 
fever, tachycardia, diaphoresis and nausea, with possible hypertension, chest pain and 
amnesia [73]. This reaction is consistent with an immunoglobulin E-stimulated response 
[72]. The development and use of homogeneous heparin compounds could prevent many of 
these unwanted effects: first, because the dosing and anticoagulation would be much more 
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predictable, and second, because the compounds could be designed to avoid interaction 
with immunogenic molecules.  
 For certain heparin applications, particularly surgery, the availability of an antidote is 
imperative. Additionally, unstopped hemorrhaging as a result of heparin therapy can lead to 
long-term debilitating diseases and may be life threatening [74]. Protamine sulfate can be 
used to reverse unfractionated heparin, although heparin rebound is a concern, but it is 
ineffective with low-molecular-weight heparin and Arixtra [75].  Excessive bleeding due to 
Arixtra, although rare, can be very difficult to manage because of its long half-life [76]. It has 
been successfully managed with fresh frozen plasma and prothrombin complex 
concentrates [75], but the only systematically evaluated reversal for pentasaccharide 
heparins is the use of recombinant FVIIa [76]; however, the use of rFVIIa for hemorrhage is 
still controversial [77]. Novel heparin drugs would ideally be reversible by protamine to 
evade life-threatening bleeding episodes.  
 Finally, the metabolic route and rate by which heparin is cleared from the body can 
make it ideal or dangerous depending on the patient population. Long-acting heparins suit 
patients that require long-term therapy, and short-acting heparins better treat those 
undergoing surgery or at risk for anticoagulant complications. In addition, clearance by the 
liver is preferred over kidney clearance, as many patients have kidney impairment that 
results in the accumulation of short heparins like Arixtra [78]. Although length is known to be 
a determining factor, the structure of heparin required for liver clearance has not been 
previously described. Taking the aforementioned considerations into account, we sought to 
determine the structure-function relationships of synthesized heparins with the goal of 
designing heparins that had improved safety, administration, clearance and reversibility 
profiles to the existing drugs.     
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Statement of Problem 
 
 Heparin has been widely used for decades, but it has several limitations as a drug. 
Unfractionated heparin has contamination issues due to its sourcing and causes side effects 
like heparin-induced thrombocytopenia. Low-molecular-weight heparin can cause severe 
bleeding due to its structural heterogeneity. Pentasaccharides like Arixtra are unsafe for 
kidney impaired patients due to their renal clearance route [79]. The goals of this 
dissertation were to characterize the protein interactions underlying some of these 
drawbacks and to propose improved heparin structures.  
 Recent advances in heparan sulfate synthesis using a chemoenzymatic approach 
have enabled the production of novel molecules with desired sulfation patterns and lengths 
(for a review, see [80]). First, this synthetic approach was used to investigate methods to 
reduce binding between heparan sulfate and PF4, an interaction that initiates heparin-
induced thrombocytopenia. In addition, we sought to characterize the structural 
requirements for binding to Stabilin receptors, which were recently identified as heparin 
clearance receptors [81]. We hypothesized that heparan sulfate structures with robust 
binding to Stabilins would be cleared by the liver and cleared more quickly than non-binding 
ones. During these studies, bioavailability and affinity for coagulation factors (Xa and IIa) 
were also investigated. The results of these studies should provide insight into the 
mechanisms underlying heparin’s properties in the body and also suggest meaningful 
strategies for the development of improved heparin drugs.  
 
 
 
 
 
 
 
 
 
 
CHAPTER II 
MATERIALS AND METHODS 
 
Expression of HS biosynthetic enzymes   
Several enzymes were used for HS synthesis, including NST, C5-epi, 2-OST, 6-OST-1, 6-
OST-3, 3-OST-1, 3OST-5, KfiA, and pmHS2.  All enzymes were expressed in E. coli and 
purified by appropriate affinity chromatography as described previously [82].   
 
Preparation of 35S-labeled polysaccharides 
Radiolabeled polysaccharide substrates were prepared using approximately 1 µg 
heparosan, a capsular polysaccharide isolated from the E. coli K5 strain, as a starting 
material [83]. Other substrates were prepared from bovine kidney heparan sulfate. The 
starting materials were modified with 5-10 µg of C5-epi, NST, 6OST-1/3, 2OST, 3OST-1 and 
3OST-5 enzymes in sequential 200-µL reactions containing approximately 1 x 106 cpm 
[35S]PAPS and 10 nmol unlabeled PAPS in 50 mM MES (pH 7) and 0.5% triton X-100. The 
enzymatic reactions were incubated at 37°C for 60 min, heat inactivated and purified using a 
DEAE column [83].  
 
Expression of recombinant Sulf-2 in CHO cells   
A plasmid consisting of a full-length cDNA encoding human Sulf-2 was purchased from 
Open Biosystem (Clone ID #7969293). The gene was cloned into a pcDNA3.1A mammalian 
expression vector (from Invitrogen) using XhoI/HindIII sites to obtain a Sulf-2 expression 
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plasmid designated as pcDNA3.1A-myc/His-HSulf-2. Wild-type CHO cells were transiently 
transfected with the expression plasmid pcDNA3.1A-myc/His-HSulf-2 or an empty 
pcDNA3.1A vector according to a standard protocol. Briefly, CHO cells were seeded in 6-
well plates in F-12 media supplemented with 10% fetal bovine serum (FBS) and were 
maintained in a 5% CO2 humidified incubator at 37°C. When the cells reached 90-95% 
confluence, they were transfected using Lipofectamine 2000 reagent (Invitrogen) and Opti-
MEM Reduced Serum Media (Invitrogen) according to the manufacturer’s protocol. After 4-6 
h, the medium was replaced with F-12 media containing 10% FBS. The conditioned medium 
was collected after 48-72 h of incubation and centrifuged at 4,000 rpm for 15 minutes to 
remove cellular debris. 
 
Western blotting 
Sulf-2 and EV-transfected cells were collected using trypsin and washed with PBS. Cells 
were lysed with 1.5 M sucrose, 1% triton X-100 and 1 mM PMSF. Sulf-2 and EV CM and 
lysates were separated by 12% SDS-PAGE and visualized with an anti-myc primary 
antibody (Cell Signaling Technology) and the SuperSignal detection system (Thermo 
Scientific). 
 
Sulf-2 enzymatic assay  
A 100-µL reaction containing 35S-labeled substrate, 50 mM MES (pH 6.5), 10 mM CaCl2, 
0.1% triton X-100 and 50 µL Sulf-2 enzyme was incubated overnight at 37°C. 
Polysaccharide substrates were purified using Quick Spin Columns for radiolabeled DNA 
purification (Roche). Columns were centrifuged at 1100 x g for 2 min to remove the column 
buffer, then placed into a fresh collection tube and loaded with 50 µL of reaction mixture. 
After centrifugation for 4 min at 1100 x g, the eluate was collected and the amount of 35S-
labeled polysaccharide was quantified using a scintillation counter.  
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Analysis of synthetic polysaccharides 
To determine the structural compositions of radiolabeled substrates, disaccharide analyses 
were performed using heparin lyase digestion. Polysaccharide substrates were incubated 
overnight with a mixture of heparin lysase I, II and III (0.1 mg/mL each) in 200 µL of 50 mM 
sodium phosphate (pH 7) at 37°C. The reaction was terminated by boiling at 100°C for 5 min 
and was loaded onto a Bio-Gel P-2 column (Bio Rad) to isolate disaccharides. These 
disaccharides were analyzed using reverse-phase ion-pairing HPLC [31].  
 
Preparation of 35S-labeled HS from CHO cells 
A T-75 flask of wild-type CHO cells was grown to confluence in F-12 media supplemented 
with 10% FBS. The cells were then incubated with 1 mL of 1.0 mCi/mL sodium [35S]sulfate 
(Perkin Elmer) for 6 h at 37°C with 5% CO2. Two hundred microliters of a pronase stock 
solution containing 1 mg/mL Pronase (Sigma), 240 mM NaAcO (pH 6.5) and 1.92 M NaCl 
was added to the cells, and the flask was incubated overnight at 37°C. The pronase-
digested sample was centrifuged at 10,000 rpm for 15 min and filtered using a 0.45-µm filter, 
then purified using a DEAE-Sepharcel column (Sigma), which was equilibrated using a 
buffer containing 20 mM NaAcO (pH 5) and 150 mM NaCl.  The [35S]HS was eluted from the 
column with 1 M NaCl in 20 mM NaAcO and was dialyzed overnight against 50 mM 
ammonium bicarbonate using a 14,000 MWCO membrane, then dried. The sample was 
reconstituted in 1 mL water, and 10 µL of a solution containing 10 N NaOH and 0.89 M 
sodium borohydride was added to break the linkage between the core protein and HS. It 
was incubated at 46°C for 16 h. The sample was also treated with 20 U/mL chondroitinase 
ABC (Sigma) to remove chondroitin sulfate before use. 
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Preparation of 3OST-1-treated [35S]HS  
To 3-O-sulfate [35S]HS using unlabeled PAPS for affinity co-electrophoresis, approximately 
100,000 cpm of [35S]HS was added to a 50-µL reaction containing 0.05 ng 3OST-1, 10 mM 
MnCl2, 5 mM MgCl2, 75 ug/mL protamine chloride, 0.4 mg/mL chondroitin sulfate, 0.12 
mg/mL BSA, 1% triton X-100 and 0.5 mM PAPS. The reaction was incubated at 37°C for 20 
min, inactivated at 80°C for 10 min, then diluted with 60 µL H2O and centrifuged at 2000 x g 
for 10 min. Substrates used for antithrombin binding studies were then isolated using a 
concanavalin A-Sepharose column (Sigma). 
 
Preparation of mPF4 
The full-length murine PF4 cDNA was obtained from Open Biosystems (Clone ID: 582960). 
The heparin-binding domain of PF4 (Ala33-Ser105) was cloned into a PET32 vector 
(Novagen) using NcoI and HindIII sites to give a plasmid named as PF4-PET32/TEV. In this 
plasmid, a tobacco etch virus protease (TEV) cleavage hexapeptide sequence, EQLYFQG, 
was constructed between thioredoxin and PF4. The design permitted cleavage of the 
thioredoxin-PF4 fusion protein to release PF4. The resultant recombinant PF4 protein has 
five extra amino acid residues (GSRHG) at the N-terminus. A bacterial strain, BL21(DE3)-
RIL/pRK793, expressing TEV protease was a generous gift from Dr. Lars Pedersen 
(National Institute of Environmental Health Sciences). 
The PF4-PET32/TEV plasmid was introduced into BL21 cells, and the cells were 
grown in LB medium containing 50 µg/mL carbenicillin and induced with IPTG. The cells 
were pelleted, lysed in 25 mM Tris, 500 mM NaCl and 300 mM imidazole (pH 7.5) and 
purified using a nickel column. The fractions containing protein were collected and incubated 
overnight with TEV protease (1:25 w/w ratio of TEV:PF4). After TEV cleavage, the PF4 was 
dialyzed against 20 mM Tris and 250 mM NaCl (pH 8) and was purified with a heparin 
column, which was eluted with 250 mM to 2000 mM NaCl gradient in 20 mM Tris (pH 8). 
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The purity of PF4 was greater than 90% as determined by NuPAGE 12% Bis-Tris Gel 
(Invitrogen).  PF4 was eluted as a protein with a MW of 30 kDa on a Sephadex G75 column, 
suggesting that PF4 is present in a tetrameric form that was consistent with a previous 
report [84]. The concentration of PF4 was determined by amino acid compositional analysis. 
 
 Dot blot assay for PF4 binding 
A dot blot assay was used to determine the binding affinities of HS to PF4. 35S-labeled HS 
(approximately 6,000 cpm) was incubated with 0-15 µg/mL PF4 for 30 min at 37°C in 130 
mM NaCl, 50 mM Tris (pH 7) buffer (for the [35S]HS polysaccharide studies) or in 250 mM 
NaCl, 50 mM Tris (pH 7.3) buffer (for the oligosaccharide studies) to allow complex 
formation. The mixture was then spotted onto a nitrocellulose membrane (GE Healthcare), 
which binds to proteins nonspecifically, allowing the capture of PF4-[35S]HS complexes. The 
membrane wells were washed with buffer, then excised, and the bound radioactivity was 
quantified using a scintillation counter. 
 
Affinity co-electrophoresis 
Affinity co-electrophoresis gels were prepared using a standard protocol [85] with lanes 
containing 0-1.41 µM PF4 or 0-3.2 µM AT and approximately 50,000 cpm [35S]HS per gel. 
Gels were run for 2 (AT) or 2.5 (PF4) hours and the bands were imaged using a Storm 860 
phosphorimager (Molecular Dynamics) and ImageQuant TL v2005 software (GE Healthcare 
Life Sciences). Kd values were determined by plotting R/[protein] vs. R, where R = (Mo – 
M)/Mo; Mo = the mobility of free HS and M = the mobility of HS at each protein 
concentration. The slope is equal to -1/Kd.  
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AT binding assay  
To quantify the binding of Sulf-2-treated and untreated HS to AT, 3OST-1-labeled substrates 
were incubated with 0.1 mg/mL AT, and the complex of AT and HS was captured using 
concanavalin A-Sepharose beads (Sigma). For this experiment, the AT-binding [35S]HS was 
prepared by incubating HS from bovine kidney with the 3OST-1 enzyme and [35S]PAPS.  
 
Preparation of enzyme cofactors   
A sulfo donor, 3’-phosphoadenosine 5’-phophosulfate (PAPS), was prepared using 
adenosine phosphokinase and ATP-sulfurylase [82].  The preparation of UDP-GlcNTFA was 
started from glucosamine (Sigma), which was first converted to GlcNTFA by reacting with S-
ethyl trifluorothioacetate (Sigma-Aldrich) following the protocol described previously [82]. 
The resultant GlcNTFA was converted to GlcNTFA-1-phosphate using N-acetylhexosamine 
1-kinase [86].  The plasmid expressing N-acetylhexoamine 1-kinase was a generous gift 
from Prof. Peng Wang (Georgia State University), and the expression of the enzyme was 
carried out in E. coli as reported [86].  The UDP-GlcNTFA synthesis was completed by 
transforming GlcNTFA-1-phosphate using glucosamine-1-phosphate acetyltransferase/N-
acetylglucosamine-1-phosphate uridyltransferase (GlmU) as described [82].  The resultant 
UDP-GlcNTFA was then ready for the elongation reaction using KfiA. 
 
Preparation of oligosaccharide backbone 
A disaccharide (GlcA-AnMan) was prepared from heparosan as described [82].  The 
disaccharide was then elongated to N-TFA oligosaccharides by repetitive exposure to KfiA, 
pmHS2, UDP-GlcNTFA and UDP-GlcA as shown in Fig 1. Briefly, the disaccharide (20 mg), 
KfiA (30 µg/mL) and UDP-GlcNTFA (500 μM) were mixed in 120 mL of 50 mM Tris buffer.  
The reaction was incubated at room temperature overnight.  The completion of the reaction 
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was monitored by the disappearance of UDP-GlcNTFA using a silica-based polyamine 
HPLC column (PAMN-HPLC, Waters).  Once the reaction was completed, pmHS2 (30 
µg/mL) and UDP-GlcA (750 μM) were added, and the reaction was incubated for another 24 
hours at room temperature. The resultant product was a tetrasaccharide, which was purified 
by a Biogel P-2 column (0.75 × 200 cm) that was equilibrated with 0.1 M ammonium 
bicarbonate at a flow rate of 6 mL/h. The fractions were then subjected to ESI-MS analysis.  
The fractions containing the tetrasaccharide were pooled. The procedures for synthesizing 
the N-TFA pentadecasaccharide (15-mer), N-TFA heptadecasaccharide (17-mer), N-TFA 
nonadecasaccharide (19-mer) and N-TFA henicosasaccharide (21-mer)  were essentially 
the same completed by repeating the above cycle with the designated times.   
When the backbone was elongated beyond octasaccharide, a special method was 
employed to deplete the UDP-GlcNTFA and UDP-GlcNAc prior to the further elongation by 
pmHS2.  If unreacted UDP-GlcNTFA of UDP-GlcNAc was present in the GlcA elongation 
step involving pmHS2, an uncontrolled elongation occurred, resulting in a mixture.  It is, 
therefore, especially important to avoid the formation of mixtures when the synthesis 
reached octasaccharide and beyond because the P-2 column cannot separate 
oligosaccharides larger than octasaccharides. To this end, disaccharide (GlcA-AnMan) was 
added to the reaction to exhaust the residue UDP-GlcNTFA and GlcNAc at the reaction, and 
the resultant trisaccharide was removed by the P-2 column. 
 
N-detrifluoroacetylation  
Oligosaccharide backbones (1 to 2 mg) were resuspended in a solution (20 mL) containing 
CH3OH, H2O and (C2H5)3N (v/v/v = 2:2:1). The reaction was incubated at 50°C overnight.  
The samples were dried and reconstituted in H2O to recover de-N-trifluoroacetylated 
oligosaccharides. 
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N-sulfation of oligosaccharides   
N-sulfation of oligosaccharide was carried out by incubating the oligosaccharide substrates 
with NST and PAPS. The reaction mixture typically contained 1-2 mg de-N-
trifluoroacetylated oligosaccharide, 500 µM PAPS, 50 mM MES, pH 7.0 and 1 mg of NST in 
a total volume of 15 mL.  The reaction mixture was incubated at 37°C overnight.   
 
Sulfation and epimerization modifications of oligosaccharide backbones  
The conversion of N-sulfo oligosaccharides to final products involved three steps, including 
C5-epimerization/2-O-sulfation, 6-O-sulfation and 3-O-sulfation.  N-sulfo oligosaccharides (1-
2 mg) were incubated with a reaction mixture containing 50 mM MES, pH 7.0, 0.03 mg/mL 
C5-epi and 2 mM CaCl2 in a total volume of 40 mL.  After incubating 30 min at 37°C, 2-OST 
(0.03 mg/mL) and 200 µM PAPS were added, and the reaction was incubated overnight at 
37°C. The products were purified by a DEAE column described previously (14).  For 6-O-
sulfation, the substrate was incubated with a reaction mixture containing 50 mM MES, pH 
7.0, and 500 µM PAPS overnight at 37°C in the presence of 6-OST-1 (0.03 mg/mL) and 6-
OST-3 (0.03 mg/mL) in a total volume of 20 mL overnight at 37°C. The products were 
purified by a DEAE column.  For 3-O-sulfation, the reaction mixture contained 3-OST-1 (0.03 
mg/mL), 10 mM MnCl2, 5 mM MgCl2, and PAPS 500 µM in a total volume of 20 mL overnight 
at 37°C.   
 
Mass spectrometric analysis of oligosaccharides  
The analyses were performed with a Thermo LCQ-Deca. The nonsulfated oligosaccharide 
(1 µL) eluted from BioGel P-2 was directly diluted in 200 µL of 9:1 MeOH/H2O. A syringe 
pump (Harvard Apparatus) was used to introduce the sample via direct infusion (35 µL 
/min). Experiments were carried out in negative ionization mode with the electrospray source 
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set to 5 KV and 275°C. Sulfated oligosaccharide (1 µL) was diluted in a different working 
solution containing 200 µL of 70% acetonitrile and 10 mM imidazole.  Experiments for 
sulfated oligosaccharides were carried out in negative ionization mode with the electrospray 
source set to 2 KV and 200°C.  The automatic gain control was set to 1 X 107 for full scan 
MS. The MS data were acquired and processed using Xcalibur 1.3. 
 
Inhibition of the activities of factor Xa and IIa  
Assays were based on a previously published method [87, 88]. Briefly, factor Xa (Enzyme 
Research Laboratories, South Bend, IN) and thrombin (Sigma) were diluted at 80 nM and 
100 nM, respectively, with PBS containing 1 mg/mL BSA. Human AT (Cutter Biological) was 
diluted with PBS containing 1 mg/mL BSA to give a stock solution at the concentration of 0.4 
µM. The chromogenic substrates, S-2765 (for factor Xa assay) and S-2238 (for factor IIa 
assay) were prepared at 1.3 mM and 1.5 mM in water. The synthesized oligosaccharides or 
heparin was dissolved in PBS at various concentrations (1 to 30 nM). The reaction mixture, 
which consisted of 70 µL of AT stock solution and 15 µL of the sample solution, was 
incubated at room temperature for 2 min.  Factor Xa or thrombin (10 µL) was added. After 
incubation at room temperature for 4 min, 30 µL of S-2765 or S-2238 was added. The initial 
reaction rates as a function of concentration were used to calculate the IC50 values. The 
absorbance of the reaction mixture was measured at 405 nm continuously for 10 min. The 
absorbance values were plotted against the reaction time. The initial reaction rates as a 
function of concentration were used to calculate the IC50 values.   
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The neutralization effect of PF4 on anti-Xa activity 
HS oligosaccharides were incubated in a 96-well plate with 70 µL BSA (1 mg/mL in PBS), 
10 µL AT (0.2 mg/mL in PBS) and 0-16 µL PF4 (0.45 mg/mL) for two minutes at room 
temperature. Ten microliters of Xa was then added, and after four minutes, 30 µL of 
chromogenic substrate S-2765 (1 mg/mL) was added to initiate the color change reaction. 
Sequential absorbance readings at 405 nm were started immediately using an ELx808 plate 
reader (BioTek). The rate of increased absorbance relative to the rate of a control sample 
was used to define Xa activity. Quantities of oligosaccharides showing approximately 8% Xa 
activity in the absence of PF4 were used.  
 
HPLC analysis of oligosaccharides 
Both DEAE-HPLC and polyamine-based anion exchange (PAMN)-HPLC were used to 
determine the purity of the oligosaccharides. The elution conditions for the HPLC analysis 
are described in the literature [82].   
  
Nitrous acid-degraded disaccharide analysis of 35S-labeled oligosaccharides  
The 35S-labeled compound was deacetylated and degraded with nitrous acid at pH 4.5, then 
at pH 1.5, followed by reduction with sodium borohydride as described by Shively and 
colleagues [89]. The resultant 35S-labeled disaccharides were resolved by a C18 reverse-
phase column (0.46 × 25 cm) (Vydac) under reverse-phase ion pairing HPLC conditions.  
The identities of the disaccharides were determined by coeluting with appropriate 35S-
labeled disaccharide standards.  
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Materials, solutions and buffers for Flp-In 293-based assays  
Heparin (or unfractionated heparin) was from Sigma (St. Louis, MO).  Fondaparinux 
(Arixtra®) was purchased from a local pharmacy.   Flp-In 293 cells, serum, and high glucose 
Dulbecco’s Modified Eagle Medium (DMEM) were from Gibco, Hygromycin B, Zeocin, and 
glutamine were from Invitrogen/Gibco (Carlsbad, CA).  Western blot analysis was completed 
by either colorimetric or chemiluminescence detection of blotted protein. Anti-V5 antibodies 
and resins were from Bethyl Laboratories (Montgomery, TX).  Other materials, reagents and 
kits were obtained as described recently [90].  Tris-buffered saline with Tween-20 (TBST) 
contains 20 mM Tris-HCl, pH 7.0, 150 mM NaCl, and 0.1% Tween-20. TBST/BSA is TBST 
with 1.0% (w/v) bovine serum albumin (BSA).  Phosphate buffered saline (PBS) contains 
137 mM NaCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, 2.7 mM KCl, pH 7.2.  Hank’s buffered 
saline solution (HBSS) contains 5 mM KCl, 0.4 mM KH2PO4, 0.8 mM MgSO4, 137 mM NaCl, 
0.3 mM Na2HPO4, 5.5 mM glucose, 1.26 mM CaCl2, 0.5 mM MgCl2, and 28 μM phenol red; 
at the time of use, 3.5 g/100 mL of NaHCO3 was added and the pH was adjusted to 7.2 with 
HCl. Endocytosis Medium contains DMEM supplemented with 0.05% BSA.   
 
Preparation of 35S-labeled HS constructs for Stabilin binding studies  
A total of 27 HS constructs were prepared using a chemoenzymatic approach published 
previously [91, 92]. Constructs 14 through 23 are polysaccharide constructs differing in 
sulfation types and IdoA content, while construct 24 through 36 are oligosaccharide 
constructs ranging from hepta- to nonadeca-saccharides (Table 4.1).  A representative 
structure of a decasaccharide (28b) is shown in Fig. 4.10. For the synthesis of 
polysaccharide constructs (14 through 23), N-sulfo heparosan was used as a starting 
material and incubated with appropriate enzymes and the sulfo donor 3’-phosphoadenosine 
5’-phosphosulfate (PAPS) [91]. The polysaccharide products were analyzed by disaccharide 
28 
 
analysis to confirm the anticipated sulfations [93]. To prepare the oligosaccharide constructs 
(24 through 36), both elongation and modification steps were involved. During the 
elongation step, a disaccharide starting material (GlcA-AnMan) was first elongated to the 
desirable size with KfiA (N-acetyl glucosaminyl transferase of E. coli K5 strain) and pmHS2 
(Pasteurella multocida heparosan synthase 2) in the presence of UDP-GlcA and UDP-
GlcNAc or UDP-GlcNTFA. The elongated products were confirmed by electrospray 
ionization mass spectrometry (ESI-MS).  The oligosaccharides were then converted to N-
sulfo oligosaccharides by treating with triethylamine followed by N-sulfotransferase 
modification. The products were demonstrated to have the anticipated molecular size and 
purity by ESI-MS.  
The oligosaccharides were then modified by C5-epimerase (C5-epi), 2-O-
sulfotransferase (2-OST), 6-O-sulfotransferase 1 and 3 (6-OST-1 and 6-OST-3) and 3-O-
sulfotransferase 1(3-OST-1).  After the modifications, a mixture of oligosaccharides with 
different levels of sulfation was obtained as determined by DEAE (diethylaminoethyl)-HPLC.  
To introduce a 35S-label to the polysaccharides or oligosaccharides, [35S]PAPS replaced 
unlabeled PAPS.  3-O-[35S]sulfated heparin was prepared by incubating heparin with 3-OST-
5 enzyme and [35S]PAPS, and the product was purified by DEAE chromatography. 
The procedures for preparing the N-sulfo heparosan, PAPS and [35S]PAPS, UDP-
GlcNTFA and disaccharide (GlcA-AnMan) starting materials are described elsewhere [82, 
91, 94]. The enzymes used for the synthesis, including KfiA, pmHS2, NST, C5-epi, 2-OST, 
6-OST-1, 6-OST-3 and 3-OST-1, were expressed in E. coli as described previously [92]. 
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Stabilin expression plasmids  
The cDNA for human Stab1 (a kind gift of J. Kzhyshkowska, University of Heidelberg) and 
Stab2/315-HARE were ligated into the MCS of the pcDNA5/FRT/V5-6xHIS-TOPO vector.  
The Stab2/190-HARE cDNA encoding the C-terminal 1416 aa is cloned in 
pSecTag/FRT/V5-6xHIS-TOPO, which provides a secretion signal for the 190-HARE protein 
[95].  Plasmids encoding the secreted ecto-domain were generated by single primer deletion 
mutagenesis [96] in which the transmembrane and cytoplasmic domain encoding regions 
were deleted, and the resulting plasmids were then used to create stable cells which 
secreted properly folded and functional ecto-domains in the medium.  The ecto-domains 
comprised amino acids M1-P2475 for Stab1, M1-T2458 for Stabilin-2/315-HARE, and 
S1136-V2453 for Stab2/190-HARE.  
 
Endocytosis assays 
Stably transfected cells expressing Stab-1 or Stab-2 receptors or only Hygromycin B 
resistant (empty vector, EV) were plated in 24-well dishes and grown in DMEM with 8% FBS 
and 50 μg/mL Hygromycin B for at least 2 days prior to the experiments.  The cells were 
incubated at 37˚C for 3 h with fresh Endocytosis Medium supplemented with labeled 35S-HS 
constructs (2.0 x 104 cpm/mL).  For those experiments utilizing AT, the 35S-HS constructs 
were pre-incubated with AT (0.2 mg/mL) for 30 min prior to diluting ten-fold in endocytosis 
medium.  Specific binding or endocytosis was assessed in the presence of excess 
unlabeled heparin (0.1 mg/mL) to determine background cpm (counts per minute) values. 
These values were subtracted from all data points to determine specific 35S-HS endocytosis.  
At the termination times, cells were washed three times with ice-cold Hank’s buffered saline 
30 
 
solution, lysed in 0.3 N NaOH, and radioactivity and protein content were determined and 
expressed as cpm/µg protein ± standard deviation of the mean. 35S radioactivity of all 
samples was measured by a Beckman-Coulter LS6500 scintillation counter.  Non-specific 
binding/background radiation levels were consistently between 16 and 20 cpm for all 
experiments. 
 
Direct ectodomain binding assays  
To assess direct protein-HS binding, ecto-domains of each receptor were expressed and 
secreted in stable cell lines. The ecto-domains were immunoprecipitated with a goat anti-V5 
resin (Bethyl labs), washed with TBS and then incubated with 4.0 x 105 cpm of each 35S-HS 
construct for 1.5 h under rotation. The resin was centrifuged, washed 3 times with TBS, then 
placed in scintillation fluid and quantified by a Beckman-Coulter LS6500 scintillation counter. 
The amount of protein on the resin was quantified by separation with 5% SDS-PAGE, 
blotted, probed with rabbit anti-V5 antibody (Bethyl labs), and images were captured on film.  
  
Assessment of liver clearance 
All animal procedures were approved by the IACUC of the University of Nebraska under the 
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) 
guidelines. BALB/c mice were placed under general anesthesia (isoflurane) on a warming 
platform during the entire procedure. Once unconsciousness was confirmed, the mice were 
injected via the lateral tail vein using a 27G x 1/2 needle with 0.053 µCi 35S-labeled HS 
construct. The radiolabeled material was allowed to circulate for 10 min, followed by 
abdominal exposure and severance of the descending aorta abdominalis for bleed out.  The 
liver was collected, briefly washed to get rid of residual blood, cut into smaller (~0.1 g) 
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pieces, weighed and then homogenized with a PowerGen 125 (Fisher) tissue homogenizer 
in 0.75 mL 1% NP-40. Homogenized tissue was then spun at 12,000 x g for 2 min to clear 
out insoluble material, and supernatants were mixed with 4 mL scintillation fluid and 
counted. 
 
Synthesis of pure pnp-tagged oligosaccharides 
Oligosaccharides were elongated from a 1-O-(para-nitrophenyl) glucuronide (GlcA-pnp) 
monosaccharide (Sigma) using KfiA and pmHS2. The oligosaccharides were modified using 
2OST, C5-epi, 6OSTs and 3OST-1. Controlled additions of GlcNAc and GlcNTFA sugars in 
the backbone to prepare a GlcNTFA-GlcA-GlcNS-GlcA-GlcNS pentasaccharide region 
allowed exploitation of the irreversible reaction mode of C5-epi on the underlined GlcA. This 
IdoA was then 2-O-sulfated. Next, the GlcNTFA was converted to a GlcNS and another 
GlcNTFA-GlcA was added to the nonreducing end so that the next GlcA could be converted 
to IdoA2S. Subsequent cycles prepared pure oligosaccharides that contained repeating 
GlcNS6S-IdoA2s regions. The reactions were purified using a C18 column (0.75 × 20 cm, 
Biotage), and the product was identified by its absorbance at 310 nm and later by mass 
spectroscopy.  
 
Protamine reversibility assays 
Quanitities of HS oligosaccharides that displayed 90% inhibition of factor Xa were incubated 
in a standard chromogenic anti-Xa assay with human serum and 0-2.6 µg/mL protamine. 
Anti-Xa activity was measured by the decrease in the rate of absorbance at 405 nm 
compared to a control sample without heparin. 
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Clearance profile of anti-Xa activity in rats  
Male Sprague-Dawley rats were dosed with amounts of Lovenox or Arixtra having 
equivalent anti-Xa activity: 2.27 mg/kg for Lovenox and 0.2 mg/kg for Arixtra. The drugs 
were diluted in saline and injected subcutaneously at a volume of approximately 100 µL. 
Blood (approximately 50 µL) was collected from unanesthetized rats at set time intervals by 
the tail clip method, then spun down to isolate plasma. The plasma was subjected to anti-Xa 
activity assays. All rat procedures were approved by the UNC IACUC.  
 
Anti-Xa activity in mice 
Male BALB/c mice from Charles River Laboratories were injected subcutaneously with 100 
nmoles of oligosaccharide per kg body weight. The oligosaccharides were diluted in saline 
and the injection volume was approximately 100 µL. Thirty minutes after injection, the mice 
were sacrificed with a CO2 chamber and approximately 0.5 mL of blood was immediately 
drawn by cardiac puncture. The blood samples were centrifuged to obtain plasma, which 
was used for analysis of anti-Xa activity. Plasma from mice injected with saline was used as 
a control. 
 
 
 
 
 
 
 
 
 
CHAPTER III 
REDUCTION OF PLATELET FACTOR 4 BINDING TO HEPARAN SULFATE 
 
 One of the most dangerous side effects associated with the use of heparin is 
heparin-induced thrombocytopenia, or HIT. HIT results in platelet degradation and a 
prothrombotic state and occurs in up to 5% of patients receiving unfractionated heparin [97]. 
HIT is initiated by the formation of HS-platelet factor 4 complexes that are recognized by 
platelet-activating antibodies to invoke an immune response [98]. Thus, decreased binding 
between HS and PF4 could prevent the formation of these complexes and the likelihood of 
HIT. 
 Platelet factor 4 (PF4) belongs to the CXC family of chemoattractant chemokines. 
The interaction between HS and PF4 is mediated by negatively charged sulfo groups on the 
HS backbone interacting with positively charged residues on the PF4 protein, which is 
released from alpha-granules upon vascular injury [99]. However, little is known about the 
specific HS sulfation patterns and length required for this interaction. Based on a preliminary 
examination of HS-PF4 binding in our laboratory, we hypothesized that the removal of 6-O-
sulfation should reduce the binding of HS to PF4. Sulf-2, a 6-O-endosulfatase, is known to 
remove these negatively charged 6-O-sulfo groups from HS, and its role in mediating HS-
PF4 binding was investigated. The substrate specificity of Sulf-2 was also explored. 
The Sulfs are known to have endosulfatase activity and remove 6-O-sulfo groups 
from HS [100, 101]. Two Sulf enzymes (Sulf-1 and Sulf-2) have been identified, cloned and 
expressed in several cell lines [100-104]. The two Sulfs appear to be functionally redundant 
and have varied roles in cell signaling, development and cancer. The Sulfs 
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promote some signaling pathways, such as Wnts [100, 105, 106], bone morphogenic protein 
[107] and glial cell-derived neurotrophic factor [108] while inhibiting others, such as 
fibroblast growth factor-2 [109, 110] and transforming growth factor-β [111]. Gene 
knockdown [100] and knock-out studies [108, 112-114] have shown the importance of Sulfs 
in development; these mice show aberrant growth, muscle innervation, skeletal tissue, and 
lung development. In cancer, Sulfs are believed to possess both pro-oncogenic [115-117] 
and tumor suppressing [110, 118, 119] activities. Overexpression of Sulf-2 in particular was 
recently found to promote carcinogenesis in non-small-cell lung carcinomas, pancreatic 
cancer and hepatocellular carcinoma [120, 121]. Sulf-2 also regulates receptor tyrosine 
kinase pathways and tumor growth in glioblastoma [122], making it an attractive target for 
cancer therapy. 
The Sulfs are understood to cleave 6-O-sulfo groups from trisulfated (N-, 2-O- and 6-
O-sulfated) disaccharides [101]. However, the extent of their substrate specificity and their 
ability to recognize other disaccharides is not well understood, largely due to the fact that 
polysaccharides with defined sulfation types were unavailable. In previous studies, only 
substrates containing this trisulfated motif have been used to test Sulf-2 activity [101, 123]. 
Utilizing our ability to control the sulfation types in HS polysaccharides using biosynthetic 
enzymes [37], we enzymatically synthesized 35S-labeled polysaccharides that allowed us to 
test Sulf-2’s ability to recognize other disaccharide motifs. In addition, we investigated the 
effect of Sulf-2 treatment on the ability of HS to bind to antithrombin (AT) and PF4. Binding 
to antithrombin is what confers anticoagulant activity to HS: when heparin binds 
antithrombin, it induces a conformational change that increases antithrombin’s affinity for 
proteases in the blood coagulation cascade, including factors Xa and IIa. This inhibits the 
downstream production of fibrin and fibrous clots.  
In addition to the distribution of negative charges, we hypothesized that the size of 
HS contributes to its PF4 binding affinity. We investigated the relationship between the 
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length of HS oligosaccharides and their interaction with PF4 and coagulation factors. An AT-
binding pentasaccharide sequence is sufficient for anti-Xa activity, but if the HS chain is long 
enough, it is capable of forming a ternary complex with antithrombin and factor IIa (also 
called thrombin). The ratio between factor IIa and Xa activity is an important component of 
heparin drugs: activity against both coagulation factors is preferred, as it is expected to infer 
more reliable anticoagulation. Previous studies indicated that to obtain anti-IIa activity, a 
heparin fragment of approximately 5,000 Da (roughly an 18-mer) was necessary [124]. Our 
group prepared a set of oligosaccharides ranging from a 15- to 21-mer to investigate the 
minimum length requirement for anti-IIa activity, and the PF4 binding capabilities of these 
oligosaccharides were tested. This information could be useful in designing heparins with a 
high anti-IIa/-Xa ratio and reduced PF4 binding.   
 
Substrate specificity of Sulf-2 
 The Sulf-2 enzyme was transiently expressed in CHO cells to obtain the Sulf-2 
protein for the substrate specificity study. The recombinant Sulf-2 enzyme was detected in 
both the cell lysate and in the conditioned medium, as measured by western blot analysis 
(Fig. 3.1D). The recombinant Sulf-2 enzyme was harvested from the conditioned medium of 
transfected CHO cells. To test the activity of the crude protein, [35S]HS isolated from CHO 
cells that had been metabolically labeled with sodium [35S]sulfate was subjected to Sulf-2 
treatment. The resultant HS was digested with heparin lyases to disaccharides for 
disaccharide compositional analyses. The HPLC chromatograms of the disaccharide 
analysis of Sulf-2-treated, empty vector-treated and untreated [35S]HS samples (Fig. 3.1) 
show a clear decrease in the trisulfated ΔUA2S-GlcNS6S peak in the Sulf-2-treated sample 
with an increase of the corresponding free [35S]sulfate and ΔUA2S-GlcNS peaks. This 
suggested that the enzyme was indeed active, and it could remove 6-O-sulfo groups located 
on UA2S-GlcNS6S disaccharides as described in previously published reports [101, 123]. 
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Figure 3.1. Disaccharide composition of Sulf-2-treated and untreated [
35
S]HS. [
35
S]HS from CHO 
cells was digested with heparin lyases and analyzed by RPIP-HPLC. A. Disaccharide composition of 
untreated [
35
S]HS. Peak 2, ΔUA-GlcNS; peak 3, ΔUA-GlcNac6S; peak 4, ΔUA-GlcNS6S; peak 5, 
ΔUA2S-GlcNS; peak 6, ΔUA2S-GlcNS6S. B. Disaccharide composition of EV-treated [
35
S]HS. Peak 
2, ΔUA-GlcNS; peak 4, ΔUA-GlcNS6S; peak 5, ΔUA2S-GlcNS; peak 6, ΔUA2S-GlcNS6S. C. 
Disaccharide composition of Sulf-2-treated [
35
S]HS. Peak 1, free sulfate; peak 2, ΔUA-GlcNS; peak 3, 
ΔUA-GlcNac6S; peak 4, ΔUA-GlcNS6S; peak 5, ΔUA2S-GlcNS; peak 6, ΔUA2S-GlcNS6S. D. 
Western blot showing presence of the Sulf-2 protein. Cell lysates (30 µg) and CM were separated on 
12% SDS-PAGE, blotted to nitrocellulose and probed with anti-myc antibody. EV, empty vector-
tranfected cells. E. Lyase degradation products of [
35
S]HS. R1=H/SO3H, R2=H/SO3H/Ac. F. Lyase 
degradation products of Sulf-2-treated [
35
S]HS. R1=H/SO3H, R2=H/SO3H/Ac. Cleavable groups are 
shown in bold. 
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Having determined that Sulf-2 was active, we sought to determine with greater detail 
which polysaccharide substrates could function as substrates for the enzyme. To this end, a 
series of polysaccharides carrying different sulfation types with or without IdoA were 
prepared using an enzymatic approach, as demonstrated in Fig. 3.2. A 35S-label was 
strategically introduced to a specific site by a sulfotransferase, facilitating the identification of 
which sulfo groups were removed by Sulf-2. For example, construct 1, IdoA2S-[6-O-
35S]GlcNS6S, carried the 6-O-[35S]sulfo group at the N,6-O-sulfo glucosamine (GlcNS6S) 
unit. Thus, a release of [35S]sulfo groups from construct 1 after Sulf-2 treatment 
unambiguously indicated that a 6-O-desulfation reaction occurred. Construct 1 was 
prepared by incubating deacetylated heparosan with unlabeled PAPS and NST, 2OST and 
C5-epi in subsequent steps. This compound was 
35S-labeled at the 6-O position using 
[35S]PAPS and 6OST. The rest of the constructs (2-9) were prepared in a similar fashion 
using recombinant enzymes, as shown in the synthetic scheme (Fig. 3.2). The structure of 
each substrate was confirmed by disaccharide analysis as described previously [125].  
 A disaccharide analysis of the Sulf-2-treated substrate was also performed for each 
construct. The HPLC analysis of untreated and Sulf-2 treated construct 1 is shown as an 
example in Fig. 3.3. The presence of the trisulfated peak, ΔUA2S-GlcNS6S, is nearly 
completely eliminated by treatment with the Sulf-2 enzyme. The reduction of this peak is 
balanced by the appearance of a large free sulfate peak in the treated sample. In addition, 
there is a partial decrease in the ΔUA-GlcNS6S peak that contributed to the free sulfate 
peak.  
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Figure 3.2. Synthetic scheme for the 
35
S-labeled HS constructs. Heparosan or heparan sulfate were 
treated with heparan sulfate biosynthetic enzymes and PAPS to achieve the desired sulfation groups 
and epimerization of the uronic acid. In heparan sulfate, both GlcA and IdoA are present. 
35
S-labeled 
groups are shown in bold. 
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Figure 3.3. Disaccharide analysis of construct 1 before and after Sulf-2 treatment. Construct 1 is 
IdoUA2S-[6-O-
35
S]GlcNS6S, the best Sulf-2 substrate. A. Disaccharide composition of construct 1. B. 
Disaccharide composition of Sulf-2-treated construct 1; disaccharides without 
35
S-labeled groups are 
not detected. C. Lyase degradation products of construct 1.  D. Lyase degradation products of Sulf-2-
treated construct 1. Cleavable groups are shown in bold. 
 
 
 
To quickly quantify the activity of Sulf-2 against the different substrates, spin column 
assays were performed. Here, the column separates the analytes based on the size of the 
molecule. We anticipated that the [35S]sulfate would be trapped in the column while the 
intact polysaccharides would pass through the column without retardation. Substrates were 
incubated overnight in the presence of Sulf-2 or water as a control, and the samples were 
purified by QuickSpin column to determine how much 35S-radioactivity had been converted 
to smaller [35S]sulfate. The results from the spin column assays are shown in Table 3.1. 
From these assays, it is clear that the best substrate for Sulf-2 is the polysaccharide 
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containing N-, 2-O- and 6-O-sulfations. Further analysis of the susceptibility of the different 
sulfated polysaccharides to [35S]sulfate release permitted us to dissect the substrate 
specificities of Sulf-2. 
 
 
construct 
name  
repeating disaccharide  structure  [
35
S]sulfation 
level (nmoles/ug 
polysaccharide)  
control [
35
S] 
sulfate 
release (%)  
Sulf-2-treated 
[
35
S] sulfate 
release (%)  
1 [-IdoA2S-[6-O-
35
S]GlcNS6S-]n  1.7 2.7 ± 1.0 97.5 ± 0.8 
2 [-IdoA-[6-O-
35
S]GlcNS6S-]n  1.9 8.3 ± 0.1 24.3 ± 2.7 
3 [-GlcA-[6-O-
35
S]GlcNS6S-]n  1.4 6.6 ± 1.6 43.1 ± 2.4 
4 [-GlcA-[6-O-
35
S]GlcNAc6S-]n  0.1 14.2 ± 3.5 28.1 ± 1.3 
5 [-[2-O-
35
S]IdoA2S-GlcNS-]n  1.1 10.4 ± 2.6 12.6 ± 1.3 
6 [-[-2-O-
35
S]GlcA2S-GlcNS-]n  1.3 6.7 ± 1.9 13.7 ± 3.0 
7 3-O-[
35
S]HS (consisting of -GlcA-[3-
O-
35
S]GlcNS3S±6S- domains) 
1.1 13.6 12.2 
8 3-O-[
35
S]HS (consisting of -IdoA2S-
[3-O-
35
S]GlcNS3S±6S- and -GlcA-
[3-O-
35
S]GlcNS3S±6S- domains) 
0.8 10.1 13.9 
9 N-[
35
S]sulfated HS  1.6 11.7 13.2 
 
Table 3.1. Substrate specificity of Sulf-2. Synthetic substrates were incubated with or without the 
Sulf-2 enzyme and isolated from released sulfate groups by QuickSpin column. The remaining 
[
35
S]sulfate on the polysaccharide was quantified with a scintillation counter.  
 
  
The susceptibility of the nine HS constructs to sulfatase activity indicated that in 
addition to trisulfated disaccharides, Sulf-2 is able to desulfate the 6-O-sulfo group on a 
GlcNS6S disaccharide that is flanked by a nonreducing-end GlcA or IdoA residue 
(constructs 2 and 3). Construct 4, which contained GlcA-GlcNAc6S groups, experienced a 
slight loss of 6-O sulfo groups. The inability of Sulf-2 to remove sulfo groups from 5-9 
confirms that Sulf-2 cannot desulfate from the N-, 2-O- or 3-O positions.  
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Effect of Sulf-2 treatment on PF4 and antithrombin binding 
 To assess whether Sulf-2 could decrease the binding of HS to PF4, [35S]HS 
prepared from CHO cells was used due to its high specific [35S] radioactivity. A dot blot 
membrane binding assay was used to compare the PF4 binding capabilities of Sulf-2-
treated and untreated HS (Fig. 3.4A). The wells contained 6,000 cpm of Sulf-2-treated or 
untreated [35S]HS with increasing amounts of PF4. [35S]HS bound to PF4 was captured by 
the nitrocellulose membrane. The untreated samples reached a maximum binding of 66% 
with 152 nM PF4, but the Sulf-2-treated samples bound only up to 3.1% with 608 nM PF4. 
From the two binding curves, it is apparent that Sulf-2 treatment can reduce the binding of 
HS to PF4 by over ten-fold.    
AT-binding HS was prepared by incubating HS from bovine kidney with 3OST-1 and 
[35S]PAPS. A Sulf-2-treated fraction was prepared by incubating this material with Sulf-2. 
Concanavalin A (ConA)-Sepharose beads were incubated with AT and HS, and the AT-
bound HS fraction was eluted using a 1 M NaCl solution (Fig. 3.4).  When the treated and 
untreated fractions were incubated with ConA-Sepharose and AT, 52% of the untreated 
fraction and 44% of the Sulf-2-treated fraction were recovered, suggesting that Sulf-2 does 
not remove critical 6-O-sulfo groups from the AT-binding pentasaccharide within the 
polysaccharide. [N-35S]HS, which does not considerably bind AT, was used as a negative 
control.  
For a more quantitative assessment of the effect of Sulf-2 treatment on the binding 
affinities of HS to AT and PF4, affinity co-electrophoresis was performed. This is an 
established method for determining the affinity constant of radiolabeled polysaccharide 
ligands with proteins [85]. The mobility of each lane is determined, and the protein 
concentration in each lane can be used to determine a Kd value based on the Scatchard 
equation.  For antithrombin, gels containing serial dilutions from 0-3.2 µM AT were prepared 
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and 50,000 cpm of the AT-binding fraction of 3OST-1-treated [35S]HS from CHO cells was 
added. The gel was run for 2 h, dried overnight, imaged and analyzed using ImageQuant TL 
software. For the untreated and treated samples, a plot of R/[AT] vs. R gave linear slopes of 
y=-0.0949x + 0.048 (R2=0.87) and y=-0.094 + 0.44 (R2=0.95), respectively. These 
correspond to Kd values of 10.5 and 10.6 nM, indicating that the binding affinity of HS to AT 
is unaffected by treatment with Sulf-2.  
 
 
 
Figure 3.4. Effect of Sulf-2 treatment on PF4 and AT binding. A. PF4 binding assay comparing Sulf-
2-treated and untreated radiolabeled heparan sulfate.  [
35
S]HS obtained from CHO cells was 
incubated with varying amounts of PF4, and the solutions were directly applied to a nitrocellulose 
membrane. The membrane was then washed and subjected to radioactivity analysis using a 
scintillation counter. Filled circles: untreated HS; open circles: Sulf-2-treated HS. B. [
35
S]HS was 
incubated with 0.1 mg/mL AT, and the complex of AT and HS was captured using ConA-Sepharose 
beads. The AT-binding [
35
S]HS was prepared by incubating HS from bovine kidney with the 3OST-1 
enzyme and [
35
S]PAPS.  
 
 
For PF4, serial dilutions of 0-1.41 µM PF4 were used, and 50,000 cpm of 3OST-1-
treated [35S]HS from CHO cells was added to each gel. The gels were run for 2.5 h and 
analyzed as above. Linear regression slopes of y=-0.1627x + 0.1238 (R2=0.77) and y=-
0.0085x + 0.0037 (R2=0.74) were calculated for the untreated and treated substrates, 
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respectively. These correspond to Kd values of 5.47 and 117.6 nM, showing that the binding 
affinity of HS for PF4 is decreased approximately 20-fold by treatment with Sulf-2. Taken 
together, our data suggest that Sulf-2 treatment decreases the binding affinity of HS to PF4 
while the affinity to AT remains intact. 
 
 
 untreated [
35
S]HS  Sulf-2-treated [
35
S]HS  
AT 10.5 nM  10.6 nM  
PF4  5.5 nM  118 nM  
 
Table 3.2. Binding affinities of Sulf-2-treated and untreated HS to PF4 and AT. Kd values were 
determined by affinity co-electrophoresis.  
 
 
The lack of impact on AT binding led us to question whether the 3-O-sulfated 
glucosamine residue present at the center of the AT-binding pentasaccharide in HS was 
affected by Sulf-2 [126]. We compared the disaccharide composition of 3-O-[35S]sulfated HS 
with and without Sulf-2 treatment (Fig. 3.5). The disaccharide analysis revealed the 
presence of three 3-O-sulfated disaccharides: Glc-AnMan3S, IdoA2S-AnMan3S and GlcA-
AnMan3S6S. We observed that the level of the disaccharide GlcA-AnMan3S6S in the Sulf-
2-treated sample was decreased to 38% from 51%, suggesting that Sulf-2 removed a 6-O-
sulfo group from the 3-O-sulfated glucosamine residue. However, the removal of this 6-O-
sulfo group from the 3-O-sulfated glucosamine residue has no impact on the binding affinity 
to antithrombin. This observation is consistent with the fact that AT-binding HS is composed 
of a disaccharide unit of GlcA-GlcNS3S (without a 6-O-sulfo group in the disaccharide unit) 
and GlcA-GlcNS3S6S (with a 6-O-sulfo group in the disaccharide unit) [127]. 
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Figure 3.5. Disaccharide analysis of 3-O-sulfated HS with and without Sulf-2 treatment.  The 3-O-
[
35
S]sulfated HS was prepared by incubating HS with purified 3-OST-1 enzyme and [
35
S]PAPS.  A 
portion of the 3-O-[
35
S]sulfated HS was treated with Sulf-2.  Both Sulf-2-treated and untreated HS 
were subjected to deacetylation with hydrazine followed by nitrous acid degradation at pH 4.5 and 
1.5. The resultant disaccharides were analyzed by HPLC. Panel A shows the chromatogram of the 
analysis of untreated 3-O-[
35
S]sulfated HS. Panel B shows the chromatogram of the analysis of Sulf-
2-treated 3-O-[
35
S]sulfated HS. The elution positions were identified by eluting with standards: 1 
represents GlcA-AnMan3S, 2 represents IdoA2S-AnMan3S and 3 represents GlcA-AnMan3S6S. * 
indicates the unidentified components. 
 
 
PF4 binding of oligosaccharides with anti-IIa activity 
 A small library of oligosaccharides was prepared by Dr. Yongmei Xu to investigate 
the relationship between the number of saccharide units and the anti-IIa/-Xa ratio [128]. The 
synthesis of these oligosaccharides was prepared by a novel method in which a 
disaccharide starting material (obtained by the degradation of heparosan) is sequentially 
incubated with HS elongation enzymes (KfiA and pmHS2) and UDP-sugars (UDP-GlcNAc or 
UDP-GlcNTFA and UDP-GlcA) to add one saccharide unit per step to the HS backbone. 
The backbone can then be sulfated using HS biosynthetic enzymes as previously described. 
 The PF4 binding characteristics of four oligosaccharides ranging from a 15-mer to a 
21-mer, some showing anti-IIa activity, were examined. The structures of the four 
oligosaccharides are shown in Table 3.3. 
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compound structure anti-IIa/-Xa 
10, 15-mer GlcNS6S-(IdoA2S-GlcNS6S)2-GlcA-GlcNAc6S-GlcA-GlcNac6S-GlcA-
GlcNS6S3S-IdoA2S-GlcNS6S-GlcA-AnMan 
N/A  
11, 17-mer GlcNS6S-(IdoA2S-GlcNS6S)3-GlcA-GlcNAc6S-GlcA-GlcNac6S-GlcA-
GlcNS6S3S-IdoA2S-GlcNS6S-GlcA-AnMan 
N/A 
12, 19-mer GlcNS6S-(IdoA2S-GlcNS6S)4-GlcA-GlcNAc6S-GlcA-GlcNac6S-GlcA-
GlcNS6S3S-IdoA2S-GlcNS6S-GlcA-AnMan 
1:5 
13, 21-mer GlcNS6S-(IdoA2S-GlcNS6S)5-GlcA-GlcNAc6S-GlcA-GlcNac6S-GlcA-
GlcNS6S3S-IdoA2S-GlcNS6S-GlcA-AnMan 
1:2 
 
Table 3.3. Chemical structure and anti-IIa/-Xa ratio of synthetic oligosaccharides. The AT-binding 
domain is shown in red. AnMan,anhydromannitol. 
 
 
 
Using the dot blot assay, we determined that all compounds bound to PF4; however, 
the oligosaccharides bound to PF4 to a lower extent than full-length HS (Fig. 3.6A). It should 
be noted that ULMW heparin 1 (a 7-mer) did not bind to PF4, consistent with the previous 
finding indicating that the minimum size of HS oligosaccharides that bind to PF4 is an 
octasaccharide  [129, 130]. Furthermore, the use of fondaparinux, a synthetic ULMW 
heparin, effectively eliminates the risk of heparin-induced thrombocytopenia [131, 132]. 
Next, we compared the binding affinity between the oligosaccharides and full-length 
heparin using a PF4 neutralization assay [129]. In this experiment, heparin and the 
oligosaccharides were incubated with AT and Xa. Under these conditions, the activity of Xa 
is low because of the presence of AT-saccharide complexes. Upon the addition of PF4 to 
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the reaction mixture, PF4 displaced AT by interacting with the oligosaccharides. 
Consequently, AT lost the ability to inhibit the activity of Xa. As shown in Fig. 3.6B, PF4 
effectively neutralized the inhibition effect of heparin at an ED50 of ∼1.2 μg/mL. In contrast, 
compound 13 displayed a much higher ED50 (3.4 μg/mL), suggesting that the synthesized 
21-mer has reduced binding affinity for PF4. As expected, PF4 was unable to neutralize the 
anti-Xa activity of ULMW heparin 1 because ULMW heparin 1 does not bind to PF4. 
 
 
 
Figure 3.6. Determination of the binding of PF4 to O-sulfated oligosaccharides. A. Binding between 
the 
35
S-labeled oligosaccharides and PF4 using a dot blot assay. 
35
S-labeled oligosaccharides were 
incubated with increasing amounts of PF4 and spotted onto a nitrocellulose membrane. Complexes of 
PF4 and 
35
S-labeled oligosaccharide were captured by the membrane, excised, and quantified using 
a scintillation counter. 3-O-Sulfated [
35
S]HS was used as a positive control, and it was prepared by 
incubating HS from bovine kidney and purified 3-OST-1 enzyme in the presence of [
35
S]PAPS. B. 
Neutralizing effects of PF4 on the anti-Xa activity of compound 13, heparin, and ULMW heparin 1. 
The HS compounds were incubated with AT and varying amounts of PF4 before the addition of Xa. 
AT inhibited the activity of Xa by binding to HS; PF4 competed with AT for binding to HS and 
therefore neutralizes the anti-Xa activity of AT. Chromogenic substrate was added to the mixture, and 
the rate of increase in the absorbance at 405 nm was used to determine Xa activity. 
 
 
 The ability of the compounds to bind AT was confirmed by affinity co-electrophoresis. 
If a portion of the compound mixture is unable to bind AT, two bands are expected on the 
gel: an AT-binding portion that is retarded at the top of the lane, and a non-binding portion 
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that travels partway through the lane. The complete retardation of our compounds at 
different concentrations of AT indicates that all of the mixture bound AT. 
 
 
 
Figure 3.7. Determination of the binding of compounds 10-13 to AT using affinity co-electrophoresis. 
The 
35
S-labeled compounds were loaded onto the lanes with different concentrations of AT. After 
performing the electrophoresis, the gels were imaged by phosphoimager. The 
35
S-labeled 
compounds were retarded due to the binding of AT and the oligosaccharides. ULMWH-1 represents 
the ultra-low molecular weight heparin 1, a pure heptasaccharide with a structure of GlcNAc6S-GlcA-
GlcNS3S6S-IdoA2S-GlcNS6S-GlcA-AnMan [92]. The ULMWH1 was used as a positive control 
because it was expected to bind AT completely under this condition. 
 
Conclusions 
 The results herein present two methods to produce anticoagulant HS with reduced 
binding to PF4: treatment with Sulf-2 and limited oligosaccharide length. These methods can 
aid in the design of heparin drugs with a lower incidence of HIT.  
 Understanding the full substrate specificity of Sulf-2 is of interest due to its 
involvement in development and cancer and its potential role in preparing HS structures. To 
address this issue, we synthesized nine HS polysaccharides with unique sulfation patterns 
and 35S-labeled groups at a specific position. We determined which polysaccharide 
constructs acted as substrates for Sulf-2 based on their decrease in radioactivity after Sulf-2 
treatment. We found that, as previously understood, trisulfated IdoA2S-[6-O-35S]GlcNS6S 
regions served as an excellent substrate for Sulf-2, showing approximately 90% removal of 
the radiolabeled group. In addition, this study found for the first time that disulfated UA-[6-O-
15-mer (10)      17-mer (11)        19-mer (12)          21-mer (13)           ULMWH 1 
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35S]GlcNS6S units experienced hydrolysis of 6-O-sulfo groups. Sulfation at positions other 
than the 6-O position was unable to be removed by the enzyme. These results were 
determined by spin column assay and by HPLC analysis. 
We also examined how Sulf-2 treatment affected binding to AT and PF4. Heparin 
interacts with AT through a specific AT-binding pentasaccharide: GlcNAc/NS6S-GlcA-
GlcNS3S6S-IdoA2S-GlcNS6S. It appears from our results that Sulf-2 removes 6-O-sulfo 
groups that are not within the critical AT-binding region, allowing HS to maintain its 
interaction with AT. It should be noted that the importance of 6-O-sulfation for AT-binding is 
well documented. Atha and colleagues, using a series of synthetic pentasaccharides, 
demonstrated that a particular 6-O-sulfo group on the nonreducing end side of the 3-O-
sulfated glucosamine residue contributed the AT binding energy nearly equal to that of the 
3-O-sulfo group [133]. At the polysaccharide level, 6-O-sulfation is also important for AT-
binding [37, 134]. The unique substrate specificity of Sulf-2 allows the removal of 6-O-sulfo 
groups that are nonessential for AT-binding. In addition, based on a ligand binding assay 
and affinity co-electrophoresis, we found that Sulf-2 treatment can reduce binding to PF4 on 
the order of 10- to 20-fold.  
The study of oligosaccharides with anti-IIa activity is the first to demonstrate the 
enzymatic synthesis of HS oligosaccharides up to a 21-mer. These substrates showed that 
the minimum size requirement for anti-IIa activity is a 19-mer, with a 1:5 anti-IIa/-Xa ratio, 
and that a 21-mer has a 1:2 ratio. It should be noted that these oligosaccharides, though 
defined in size, are heterogeneous in their O-sulfation patterns; however, they represent a 
significant step forward in the enzymatic synthesis of HS. All of the oligosaccharides (up to 
21 sugars in length) showed decreased binding to PF4 compared to full-length heparin in a 
dot blot protein binding assay, and the longest was less susceptible to PF4 neutralization 
than heparin in a chromogenic anti-Xa test. These results provide structural guidelines for 
new heparins with measurable anti-IIa activity and reduced PF4 interaction.   
 
 
 
 
CHAPTER IV 
IDENTIFICATION OF STABILIN-BINDING STRUCTURAL MOTIFS 
 
 Although heparin is one of the oldest drugs still in clinical use, its clearance from the 
body has remained poorly understood. Early studies on the clearance of heparin identified 
that UFH and LMWH bound and were internalized into lysosomes by human endothelial 
cells [135, 136], and it was later discovered that liver sinusoidal endothelial cells are the 
principal site for the clearance of UFH [137]. It is also known that UFH is eliminated via the 
liver and displays a fast clearance rate, while the pentasaccharide drug Arixtra is not and 
has a slow clearance rate in vivo [138]. Arixtra is instead cleared from the circulation by the 
kidneys, which makes its use in patients with renal impairment unsafe [79].  
 Recently, Stabilin-2 (Stab-2) was identified as a systemic clearance receptor for 
heparins [81]. Stabilin-2, also called HARE (hyaluronic acid receptor for endocytosis), is 
presented on the cell surface as two isoforms: a 315-kDa version and a 190-kDa version 
that is the product of proteolytic cleavage (Fig. 4.1.). Both receptors bind to heparin and 
participate in its clearance. The binding affinity of Stab-2 for UFH is higher than for LWMH, 
suggesting that the interaction between Stab-2 and heparins is dependent on the length of 
the carbohydrate chain. Stab-2 is responsible for the clearance of other 
glycosaminoglycans, such as hyaluronic acid and chondroitin sulfates, although the heparin 
binding site is known to be distinct from the LINK domain that binds these two substrates 
[90]. 
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Figure 4.1. Domain structure of Stabilin-2. 
 
 Stabilin-1 (Stab-1) is a homolog of Stab-2, with 41% amino acid identity and 56% 
similarity. It has not been previously reported to bind heparins. Like Stab-2, Stab-1 is 
expressed in the endothelium of the liver, lymph node and spleen, but it is also uniquely 
expressed in activated macrophages and continuous endothelial vasculature [139, 140], 
suggesting that the receptor is immune responsive.  
 Based on the current understanding of the role of Stabilin-2 in clearing heparin, we 
hypothesized that the binding affinity between heparin and Stab-2 likely relates to the 
clearance rate of heparin. We prepared a series of HS poly- and oligosaccharides to probe 
the structural requirements for binding to Stab-2. In addition, we tested whether the 
homologous receptor Stabilin-1 is involved in heparin clearance.  
 
Polysaccharide constructs 
 To investigate how sulfation patterns and IdoA content influenced binding to Stabilin 
receptors, ten polysaccharide constructs were chemoenzymatically prepared using 
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heparosan as a starting material. All constructs were N-[35S]-labeled using NST and 
[35S]PAPS. Subsequent sulfo groups were added using nonradiolabeled PAPS; thus, the 
cpm/µg was equal between the different constructs. The structures of the nine test 
constructs and the control (3-O-sulfo heparin) are shown in Fig. 4.2. Their structures were 
confirmed using disaccharide analysis.  
 
 
Figure 4.2. Chemical structures of the polysaccharide constructs. The top left structure shows the 
disaccharide structure of constructs without IdoA, and the top right disaccharide represents IdoA-
containing structures. The sulfo groups present for each construct are given in the table below. Bold 
groups indicate a 
35
S-label.  
 
 
 
 
Cell internalization assays 
 We tested the Stabilin-mediated cellular internalization of the ten polysaccharide 
constructs using Flp-In 293 cells. The cell lines were stably transfected with 
pcDNA5/FRT/V5-6xHIS-TOPO vectors for Stab-1, Stab-2/190-HARE and Stab-2/315-HARE. 
Transfected cells expressing the Stab-1 or Stab-2 receptors (or empty vector, Hygromycin B 
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resistant only) were plated in 24-well dishes in DMEM supplemented with 8% FBS and 50 
µg/mL Hygromycin B and grown for at least two days prior to experiments. The radiolabeled 
constructs (2.0 x 104 cpm/mL) were added to the cell cultures with fresh medium and 
incubated for 3 h.  
 The control construct 23, 3-O-sulfated heparin, was added to the cell lines to assess 
receptor binding and endocytosis (for structure, see Fig. 4.2). All three cell lines (Stab-1, 
Stab-2/190-HARE and Stab-2/315-HARE) internalized 23, as measured by the cpm/µg 
protein of the cell lysate. The expression level of Stab-2/315-HARE was previously 
determined to be lower than that of Stab-2/190-HARE; thus, its HS internalization levels 
tend to be lower. The results of the assay clearly indicated that the cell lines were capable of 
internalizing radiolabeled heparin (Fig. 4.3).  
 
 
Figure 4.3. Internalization of 3-O-sulfated heparin by Stab-1 and -2. A. 20 µg of cell lysate was 
separated by 5% SDS-PAGE, blotted onto nitrocellulose and probed with anti-V5 antibody. Lane 1, 
Stab-2/190-HARE, 2, Stab-2/315-HARE, 3, Stab-1. B. Cell lines expressing Stab-1 (white bar), Stab-
2/190-HARE and Stab-2/315-HARE (gray bars) or empty vector (black bar) were incubated with 3-O-
[
35
S]-labeled heparin for 3 h. The dotted line represents nonspecific binding. Endocytosis was 
measured as the cpm/µg cell lysate protein, mean ± s.d., n=3.  
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 Having confirmed the applicability of the cell-based assay, the nine HS constructs 
were incubated with the three cell lines under the same conditions. In general, constructs 
with more sulfo groups were more readily internalized. Surprisingly, constructs 21 and 22, 
which contained 3-O-sulfation, were endocytosed to a much higher extent than the other 
constructs (Fig. 4.4). Because 3-O-sulfation is a rare modification on HS, it is unlikely that 
the higher internalization was a simply a result of the charge density. Constructs that 
contained the same sulfo groups but differed in their IdoA content were not appreciably 
different in the internalization assay. At this time, we cannot conclude that there is any 
epimerization effect.  
 
Figure 4.4. Internalization of modified HS polysaccharides. Empty vector, Stab-1 and Stab-2/190-
HARE cell lines were incubated with HS constructs for 3 h. The cells were washed, and the [
35
S] 
cpm/µg protein cell lysate was determined with scintillation counting. Mean ± s.d., n = 3. 
 
 
Direct binding assay 
 The nine polysaccharide constructs were also tested for direct binding to purified 
Stabilin receptor ectodomains. The Stabilin receptors were isolated from the media of their 
respective cell lines using anti-V5 antibody coupled to Sepharose resin and were incubated 
HS construct:  14  15  16  17  18  19  20  21  22  
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with the 35S-labeled constructs. An empty vector cell line was used as a baseline for 
nonspecific binding due to the inherent “stickiness” of highly charged HS.  
 
  
 
Figure 4.5. Direct binding of HS constructs and Stabilin ectodomains. Secreted ectodomains of each 
receptor were immunopurified with V5 resin. A. Ectodomains were separated by 5% SDS-PAGE, 
blotted and probed with anti-V5 antibody. Lane 1, Stab-2/190-HARE, 2, Stab-2/315-HARE, 3, Stab-1. 
B-D. Ectodomains bound to V5 resin were incubated with an equal amount of each HS construct for 
1.5 h under rotation. The resin was washed three times with Tris-buffered saline and subjected to 
scintillation counting. Cpm were normalized to the amount of protein on the resin.  
 
14  15  16  17  18  19  20  21  22 
14  15  16  17  18  19  20  21  22 14  15  16  17  18  19  20  21  22 
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The binding between the nine constructs and receptor ectodomains followed a 
similar pattern to that of the cell internalization assay (Fig. 4.5). Again, constructs 21 and 22 
exhibited the highest interaction with the Stabilin receptors, and there was no observed 
difference between the constructs with IdoA and those without.  
 
Antithrombin competition  
 We noted that the structural modifications shown to provide the best binding to the 
Stabilins are the same as those that confer antithrombin binding, namely the presence of 3-
O-sulfation. This is a rare modification in HS, but it is critical for antithrombin activity. To 
discern whether AT and the Stabilins bind HS at the same site, we tested whether 
antithrombin was able to inhibit the interaction between our constructs and the Stabilin 
receptors.  
 First, Stab-1 cells were incubated with [35S]-labeled heparin and increasing 
concentrations of AT (Fig. 4.6A). Decreased heparin endocytosis with increasing AT 
indicated that some overlap between the AT-binding sequence and Stabilin-binding 
sequence does exist. Next, four of our constructs that showed at least partial Stabilin 
binding (19-22) were incubated with the three Stabilin-expressing cell lines in the presence 
and absence of AT. Constructs 19 and 20 do not contain an AT-binding site whereas 21 and 
22 do, with 21 being the best substrate for AT due to its IdoA content. Consistent with our 
previous result, constructs 21 and 22 exhibited decreased endocytosis in the presence of 
AT, while constructs 19 and 20 were unaffected (Fig. 4.6).  
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Figure 4.6. Inhibition of Stabilin-mediated endocytosis by antithrombin. A. Dose-response curve for 
AT against radiolabeled heparin. The dotted line represents the threshold for nonspecific binding. B-
E. Stabilin-binding HS constructs were incubated with the indicated cell lines in the presence or 
absence of 0.2 mg/mL AT. Constructs 8 and 9 contain an AT-binding site; constructs 6 and 7 do not. 
Data are the mean ± s.d., n = 4. 
 
AT (mg/mL) 
AT  
AT  AT  
AT  
HS without 3-O sulf (19)  HS without 3-O sulf  
and IdoA (20)  
HS with 3-O sulf (21)  HS with 3-O sulf,  
no IdoA (22)  
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Oligosaccharide constructs 
 Having determined the sulfation patterns necessary for robust Stabilin binding and 
cell internalization, we sought to determine the minimum oligosaccharide length. The 
oligosaccharide substrates were elongated (using GlcA-AnMan as a starting material) to the 
desired length, then treated with recombinant enzymes and PAPS to give the intended 
structural motifs.  A full list of the synthesized HS constructs (including polysaccharides) is 
given in Table 4.1. 
 To test the impact of length on endocytosis, oligosaccharides with 3-O-sulfation 
ranging from a 10-mer to a 19-mer (constructs 27-36) were prepared. None of these 
constructs were internalized by the empty vector cells, but surprisingly, all were taken up by 
the Stab-1 and Stab-2/315-HARE cells. A 7-mer (24) was used as a negative control and 
showed no internalization. Having determined that the minimum binding structure was 
between seven and ten sugar units, we synthesized and tested an 8-mer (25b) and 9-mer 
(26b). As shown in Fig. 4.7A, the 7-mer and 8-mer exhibit very little internalization. The 9-
mer shows a slight increase in internalization, primarily in the Stab-1 cells, while the 10-mer 
confers a significant increase in the amount of internalized HS. From this point, the amount 
of HS endocytosis remains steady up to a 19-mer, which was the largest oligosaccharide 
tested. A similar assay examined the cellular uptake of the 7-mer (not shown) and 19-mer 
with a 50-fold excess of Arixtra (Fig. 4.7B). The internalization of the 19-mer was unchanged 
by the addition of Arixtra, suggesting that Arixtra is not cleared by cells expressing Stabilin 
receptors.  
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# disaccharide repeating unit size of construct 
14 (-GlcA-GlcNS-)n polysaccharide, >6000 Da 
15 (-GlcA-GlcNS6S-)n polysaccharide, >6000 Da 
16 (-IdoA-GlcNS6S-)n polysaccharide, >6000 Da 
17 (-GlcA2S-GlcNS-)n polysaccharide, >6000 Da 
18 (-IdoA2S-GlcNS-)n polysaccharide, >6000 Da 
19 (-IdoA2S-GlcNS6S-)n polysaccharide, >6000 Da 
20 (-GlcA2S-GlcNS6S-)n polysaccharide, >6000 Da 
21 (-GlcA-GlcNS±6S±3S-)n and (-IdoA2S-GlcNS6S-)m polysaccharide, >6000 Da 
22 (-GlcA2S-GlcNS6S-)n and (-GlcA-GlcNS±6S±3S-)m polysaccharide, >6000 Da 
23 heparin, (-IdoA2S-GlcNS6S-)n and (-GlcA-GlcNS±6S±3S-)m polysaccharide, >6000 Da 
24 GlcNac6S-GlcA-GlcNS6S3S-IdoA2S-GlcNS6S-GlcA-AnMan 7-mer 
25a GlcA-GlcNS6S-(IdoA±2S-GlcNS6S)2-GlcA-AnMan 8-mer no 3-O-sulfation 
25b GlcA-GlcNS6S±3S-(IdoA±2S-GlcNS6S)2-GlcA-AnMan 8-mer with 3-O-sulfation 
26a GlcNS6S-GlcA-GlcNS6S-(IdoA±2S-GlcNS6S)2-GlcA-AnMan 9-mer no 3-O-sulfation 
26b GlcNS6S-GlcA-GlcNS6S±3S-(IdoA±2S-GlcNS6S)2-GlcA-AnMan 9-mer with 3-O-sulfation 
27 GlcA-GlcNS6S±3S-(GlcA±2S-GlcNS6S)3-GlcA-AnMan 10-mer no IdoA 
28a GlcA-GlcNS6S-(IdoA±2S-GlcNS6S)3-GlcA-AnMan 10-mer no 3-O-sulfation 
28b GlcA-GlcNS6S±3S-(IdoA±2S-GlcNS6S)3-GlcA-AnMan 10-mer with 3-O-sulfation 
29 GlcA-GlcNS6S±3S-(GlcA±2S-GlcNS6S)4-GlcA-AnMan 12-mer no IdoA 
30a GlcA-GlcNS6S-(IdoA±2S-GlcNS6S)4-GlcA-AnMan 12-mer no 3-O-sulfation 
30b GlcA-GlcNS6S±3S-(IdoA±2S-GlcNS6S)4-GlcA-AnMan 12-mer with 3-O-sulfation 
31 GlcNS6S-(GlcA±2S-GlcNS6S±3S)3-(GlcA-GlcNAc6S)2-GlcA-
GlcNS6S-GlcA-AnMan 
15-mer no IdoA 
32 GlcNS6S-(IdoA±2S-GlcNS6S±3S)3-(GlcA-GlcNAc6S)2-GlcA-
GlcNS6S-GlcA-AnMan 
15-mer 
33 GlcNAc6S-(GlcA±2S-GlcNS6S±3S)4-(GlcA-GlcNAc6S)2-GlcA-
GlcNS6S-GlcA-AnMan 
17-mer no IdoA 
34 GlcNAc6S-(IdoA2S-GlcNS6S±3S)4-(GlcA-GlcNAc6S)2-GlcA-
GlcNS6S-GlcA-AnMan 
17-mer 
35 GlcNS6S-(GlcA±2S-GlcNS6S±3S)5-(GlcA-GlcNAc6S)2-GlcA-
GlcNS6S-GlcA-AnMan 
19-mer no IdoA 
36 GlcNS6S-(IdoA2S-GlcNS6S±3S)5-(GlcA-GlcNAc6S)2-GlcA-
GlcNS6S-GlcA-AnMan 
19-mer 
 
 Table 4.1. Summary of the polysaccharide and oligosaccharide constructs.  
59 
 
 
 
Figure 4.7. Effect of size on endocytosis. A. Stab-1 and Stab-2/315-HARE cells were incubated with 
radiolabeled oligosaccharides for 3 h, washed and quanitified by scintillation counting and Bradford 
assay. B. Radiolabeled 7-mer and 19-mer were incubated for 3 h with Stab-1 and Stab-2/315-HARE 
cells with a 50-fold excess of Arixtra (Ax), then washed, lysed and quantified. The Stab-2/190-HARE 
cell line showed similar results. Data are the mean ± s.d., n = 3. 
 
  
The results up to this point strongly suggested that a 10-mer was the minimum 
length required for Stabilin binding. To further establish the role of 3-O-sulfation near this 
critical length, we prepared 8-, 9-, 10- and 12-mers without 3-O-sulfation (constructs 25a, 
26a, 28a and 30a) and with 3-O-sulfation (25b, 26b, 28b and 30b). These eight constructs 
were incubated with Stab-1 and Stab-2/315-HARE cell lines, and heparin and 7-mer were 
used as positive and negative controls. As seen in Fig. 4.8., the 7-mer, 8-mer and 9-mer 
showed little to no internalization regardless of whether they contained 3-O-sulfation. 
However, the 10-mer and 12-mer showed much higher internalization when 3-O-sulfation 
was present; in the Stabilin-1 cells, the levels of endocytosis were similar to those of 
heparin, and in the Stab-2/315-HARE cells they were about half those of heparin.  
7-mer, 24 
8-mer, 25b 
9-mer, 26b 
10-mer, 28b 
15-mer, 32 
19-mer, 36 
19-mer, 36 
19-mer, 36 + Ax 
7-mer, 11 
19-mer, 36 
19-mer, 36 + Ax 
7-mer, 11 
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Lastly, we were interested to know how Stabilin binding related to the retention of our 
constructs in the liver. The current understanding is that longer heparin chains are cleared 
by the liver, while short (non-Stabilin-binding) heparins are processed by the kidneys [138]. 
Therefore, if the Stabilins are responsible for the bulk of heparin clearance, the size and 
sulfation parameters for Stabilin binding should lead to their being taken up by the liver. 
 
 
 
Figure 4.8. A 3-O-sulfated decasaccharide is required for binding to Stabilin receptors. Stab-1 (A) 
and Stab-2/315-HARE cells (B) were incubated with heparin (positive control, black bars), 7-mer 
(negative control), 3-O-sulfated oligosaccharides (gray bars) and non-3-O-sulfated oligosaccharides 
(white bars) for 3 h. Cells were washed with Hank’s buffered saline solution and radioactivity and 
protein levels were determined, mean ± s.d., n = 3.  
 
   
Hep 
7-mer, 24 
8-mer, 25 
9-mer, 26 
10-mer, 28 
12-mer, 30 
 
Hep 
7-mer, 24 
8-mer, 25 
9-mer, 26 
10-mer, 28 
12-mer, 30 
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Figure 4.9. 3-O-sulfation leads to efficient liver retention. Mice were injected via the tail vein with 
radiolabeled heparin (black bar), 7-mer (white bar), or a 10-mer with or without 3-O-sulfation (28b, 
28a). After a short incubation, the livers were collected and processed for scintillation counting. The 
data presented are the cpm/mass of liver divided by the total cpm injected of at least three liver 
samples. n = 3 mice.  
 
 
Mice under general anesthesia were injected via the tail vein with equal amounts of 
radioactive heparin, 7-mer, 28a or 28b, and the compounds were allowed to circulate. The 
mice were then bled out, and the livers were collected and processed for scintillation 
counting. The 7-mer was not retained in the liver (Fig. 4.9, white bar), but the 3-O-sulfated 
10-mer (28b) showed retention similar to that of heparin. The non-3-O-sulfated 10-mer 
retention was significantly reduced. Thus, our data suggest that 3-O-sulfation indeed 
contributes to the uptake of heparins by the liver.  
 
Figure 4.10. The structure of 28b, the shortest HS construct that displayed robust Stabilin binding.  
Heparin 
7-mer, 24 
10-mer, 28a w/o 3-O sulf 
10-mer, 28b w/ 3-O-sulf 
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Conclusions 
Understanding the clearance rate of heparin has significant clinical implications for 
improving the safety of heparin-based drugs. For surgical applications, a fast-clearing 
heparin drug is preferred, as it would allow the anticoagulant effect to disappear rapidly after 
the operation and thus reduce the risk of bleeding side effects. In contrast, a slow-clearing 
heparin is more desirable for patients with that require repeated dosing. Indeed, UFH is 
widely used in surgical procedures and kidney dialysis, whereas LMWH and fondaparinux 
are more commonly used as prophylactic agents among high-risk patients prone to 
thrombosis [141, 142]. Although the size of the heparin chain is known to play a role in the 
rate of clearance in patients, the precise structural requirements for regulating clearance has 
remained uncharacterized. Previous studies have demonstrated that a liver endothelial cell 
receptor, known as Stabilin, is primarily responsible for heparin clearance [81]. By taking 
advantage of our laboratory’s success in synthesizing heparins [91, 92], we investigated the 
contribution of the sulfation and the size of heparin to the binding to Stab proteins. Our 
results provide a molecular basis for designing synthetic heparins with desired clearance 
rates for unique clinical applications. 
Our study revealed two binding modes between heparin and Stab proteins. In one 
binding mode, the heparin polysaccharide binds to Stab-1/-2 nonspecifically; such binding 
requires a long polysaccharide chain. Another binding mode is specific, in which the Stabilin 
proteins recognize a saccharide domain containing a 3-O-sulfo group. In the specific binding 
mode, a much shorter oligosaccharide can sufficiently display high affinity to the Stabilins. 
We also demonstrate that a 3-O-sulfated decasaccharide displays higher retention in the 
liver in mice compared to its counterpart without 3-O-sulfation, suggesting that Stabilin 
binding affinity correlates to the clearance in vivo. 
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Our data also suggest that Stabilin proteins recognize a unique saccharide 
sequence. Although we do not know the precise saccharide structure recognized by the 
Stabilin receptors at the present time, some overlaps between the Stab-binding sequence 
and AT-binding sequence exist. We know that 3-O-sulfation is a critical modification for 
displaying high binding affinity to AT and for carrying anticoagulant activity [143]. Further, 
competitive binding of the Stabilin receptors and AT to heparins was observed in this study. 
The mechanistic effect of 3-O-sulfation on the binding to the Stabilin receptors is currently 
unknown. We postulate that this effect is unlikely to be purely attributed to an increase in 
charge density because 3-O-sulfation is a rare modification in HS [144]. A recent study 
suggests that 3-O-sulfation may affect the conformation of neighboring IdoA2S residues to 
rearrange the positioning of sulfo groups [145]. In addition, previous studies have shown 
that one natural highly sulfated chondroitin sulfate (CS-D) did not compete with heparin in 
contrast to other similar chondroitin sulfates (CS-B, CS-E) that demonstrated some degree 
of competition [90], providing evidence that charge is not the only determinant for heparin 
binding to the Stabilins. 
This is the first report demonstrating the structural selectivity of heparin binding to 
Stab-1. The Stab-1 receptor is expressed in the liver sinusoidal endothelium as well as in 
alternatively activated macrophages [146] and other physiological niches [147], and it may 
play a role in both systemic and localized clearance of heparinoid molecules.  
It should be noted that the rate of endocytosis also depends on the concentration of 
Stab receptors on the cell surface. The Stab-2/190-HARE isoform always showed the 
highest increase in endocytosis because these cells produce more receptor per microgram 
of cell lysate than the other two cell lines. Not surprisingly, the liver endothelial cells exhibit a 
much higher ratio of 190/315-HARE Stab-2 than the recombinant cell lines, which may 
account for the rapid uptake of heparin within the liver [148]. The consistently lower 
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internalization rate of heparin in the Stab-1 cells may be reflective of the amount of total 
surface receptor available to bind and internalize heparin, a lower binding affinity, or the 
unavailability to bind ligand due to the very short transient time on the cell surface. Others 
have reported the very short transient time of Stab-1 on the cell surface [146, 149].  In these 
experiments, we noticed a discrepancy in binding vs. endocytosis. Our in vitro binding 
assays by immunoprecipitation of the ecto-domain of Stab-1 revealed that the binding of the 
HS oligomers was qualitatively about as high as that of the Stab-2 ecto-domains. This 
contrasts with the cell-based assays and reveals that a combination of surface availability 
and rapid turnover, not binding affinity, may be responsible for lower endocytic rates in Stab-
1 cells. In addition, the expression of Stabilin receptors can be regulated by other cellular 
mechanisms. A genetic screen in which human umbilical vein endothelial cells (HUVEC) 
activated with VEGF revealed an increase of Stab-1 expression reveals that growth factors 
and cytokines are able to alter endocytosis profiles of tissues [150].   
These results provide a molecular basis for designing anticoagulant heparin drugs 
with controlled clearance rates and advance our understanding of the HS and heparin 
clearance mechanism.  
 
 
 
 
 
 
 
  
 
 
CHAPTER V 
DESIGN OF HOMOGENEOUS HEPARINS WITH CONTROLLED CLEARANCE 
PATHWAYS 
 
 Problems with the heparin drugs available today have underscored the need for 
structurally pure heparin compounds. Most notable is the recent distribution of contaminated 
heparin that caused over 80 deaths in the United States and a major drug recall [151]. The 
heparin supply had been contaminated with oversulfated chondroitin sulfate, a related 
glycosaminoglycan is difficult to distinguish from heparin by common screening methods but 
provokes a potentially fatal immune response when administered to patients. Contamination 
issues of this nature could be avoided by replacing the porcine-derived heparin with a 
synthetic version that is not dependent on the international (primarily Chinese) pig 
population and has a shorter, better regulated supply chain.  
 Other heparin concerns can be addressed by tailoring heparin structures to have 
improved biological effects and traits desirable for different patient populations. One element 
of heparin that is essential in surgical applications is the availability of a reversal agent. 
Protamine sulfate, a highly cationic peptide, is a long-standing heparin antidote. The 
anticoagulant effect of unfractionated heparin is efficiently reversed by protamine, but 
protamine is unable to fully neutralize low-molecular-weight heparins. Thus, we investigated 
the susceptibility of our synthetic heparin compounds to protamine neutralization, with the 
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goal of designing a low-molecular-weight heparin analog with better protamine reversibility 
than existing LMWHs like Lovenox.  
 When assessing new compounds, in vitro assays, such as measurements of direct 
antithrombin binding and anti-Xa activity, give a good indication of the activities of heparin 
analogs. However, in vivo studies are necessary to investigate the biological effects and 
bioavailability of these compounds.  
 Most in vivo assays of anticoagulants involve taking timed blood samples and 
measuring a physical parameter, such as clotting, or testing for the activity of components of 
the coagulation cascade. In human patients, activated partial prothromboplastin time is the 
standard for unfractionated heparin monitoring, while more complex anti-Xa assays are 
used for patients on chronic LMWH dosing and for higher risk patients, such as infants, 
pregnant women and those with renal impairment [152-155]. Other commonly used 
research models include arterial and venous thrombosis (induced by pharmacologic or 
mechanical means) and bleeding models (such as rabbit ear bleeding and rat tail bleeding) 
[156]. Here, we used rodent models to assess anti-Xa activity.  
 
Design and synthesis of 6-, 8-, 10- and 12-mer 
 With the structural information gathered from previous studies, we set out to design 
novel anticoagulant heparin structures that were homogenous, reversible by protamine, 
cleared by the liver and short enough to have reduced PF4 binding. To this end, we 
designed heparin analogs ranging from a 6-mer to a 12-mer that contained an AT-binding 
pentasaccharide at the non-reducing end and repeating IdoA2S-GlcNS6S units (which are 
common in heparin but not heparan sulfate). Commerically available p-nitrophenyl β-
glucuronide (GlcA-pnp) was used as a starting material because the pnp tag is detectable 
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by UV at 310 nm, facilitating isolation of the product during the synthetic steps. Based on 
our previous results, we expected that the 10-mer and 12-mer would be cleared by the liver 
rather than the kidneys. The molecular weights and AT binding affinities of the constructs 
are shown in Table 5.1. 
 
 
compound molecular mass (Da) AT affinity (Kd) 
6-mer 1791.5 16.2 ± 3.7 nM 
8-mer 2368.9 13.1 ± 2.0 nM 
10-mer 2946.4 9.9 ± 4.1 nM 
12-mer 3485.8 8.5 ± 3.0 nM 
 
Table 5.1. Pure oligosaccharides for in vivo studies. All compounds contain an AT-binding motif and 
repeating IdoA2S-GlcNS6S units. Kd values were determined by affinity co-electrophoresis. 
 
 
 
Antithrombin binding affinities 
 Affinity co-electrophoresis was used to determine the binding affinities (Kd values) of 
the different constructs to AT. Each oligosaccharide was run through a gel with lanes 
containing 0-3 µM AT, and the mobility of the oligosaccharide in each lane was used to 
determine a Kd value. These values are shown in Table 5.1. The four compounds showed 
comparable binding affinities for antithrombin. 
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Protamine reversibility 
 We tested whether protamine could reverse the anti-Xa activity of the four 
compounds. The assay was similar to that used to test PF4 neutralization (Chapter III); an 
amount of each compound that was able to inhibit factor Xa by 90% was incubated with 
increasing concentrations of protamine. The return of Xa activity in the presence of 
protamine indicated that protamine was inhibiting the ability of the HS compound to bind and 
antagonize factor Xa. 
 
Figure 5.1. Susceptibility of HS oligosaccharides to protamine neutralization. HS constructs expected 
to display 90% factor Xa inhibition were added to human serum with different amounts of protamine. 
The Xa activity in the serum was then measured using a chromogenic assay. Lovenox was used as a 
control.  
 
 
 
 The experiment indicated that the two longest compounds, a 10-mer and 12-mer, 
were more susceptible to protamine neutralization than Lovenox, although they were not 
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completely neutralized. The 6-mer was not reversible by protamine and the 8-mer was 
reversed less than Lovenox. The result suggests that a pure LMWH that is 10 to 12 sugars 
long will be reversed by protamine to a greater extent than Lovenox.  
 
Pharmacokinetic profile in rats 
 Having confirmed the anti-Xa activity of the 6- to 12-mer in vitro, we were interested 
to measure their activity in a living system. Rats and rabbits are used more commonly than 
mice for anticoagulant testing because multiple blood samples can be taken from a single 
animal. Because training and facilities for rats were more readily available, we used 
Sprague-Dawley rats to test the clearance profiles of our compounds.  
  The existing drugs Lovenox and Arixtra were tested first as controls. Because these 
drugs have a half-life of 2-6 hours and 17 hours in humans, respectively, we expected that 
their half-lives in rats would be considerably different from each other and that we could use 
them as guidelines to judge whether our 6-, 8-, 10- and 12-mer showed fast clearance 
profiles (close to or shorter than Lovenox) or slow ones (more similar to Arixtra). In vitro anti-
Xa assays were performed to obtain standard curves for Lovenox and Arixtra and determine 
an equivalent dosage for the two drugs (Fig. 5.2). The doses chosen were 2.27 mg/kg for 
Lovenox and 200 µg/kg for Arixtra.  
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Figure 5.2. Pharmacokinectic profile of Lovenox and Arixtra. Standard curves of the anti-Xa activity of 
Lovenox (A) and Arixtra (B) were determined in vitro in blank rat serum. C. Rats were dosed 
subcutaneously with heparin drugs, and blood samples were taken by tail clip over a 24-hour period, 
then centrifuged to isolate plasma and subjected to a chromogenic factor Xa assay. Data points are 
the average of 2-3 samples.    
 
 
 Male rats (250-350 g) were dosed subcutaneously with approximately 100 µL of 
Lovenox or Arixtra, and blood was collected by tail clip at 0.75, 1.5, 2.25, 3, 4, 6, 8 and 24 
hours. Blood was centrifuged to obtain plasma immediately after collection and was stored 
at -20°C until use. Rat serum without drugs was used to represent 100% Xa activity (0% 
inhibition).  
 When the rat samples were assayed for anti-Xa activity, we were surprised to find 
that the two drugs exhibited a very similar plasma clearance profile (Fig. 5.2C). Although no 
published studies have compared the clearance of these two drugs in rats, a review of the 
71 
 
literature confirmed that both Lovenox and Arixtra showed a peak concentration at around 2 
hours and a half-life of about 4.5 hours in rats (for examples, see [157-159]). The long half-
lives characteristic of pentasaccharide heparin drugs like Arixtra and idraparinux (a 
fondaparinux analog with a human half-life of 80 hours) are not exhibited in animal studies 
unless a primate species (commonly baboon) is used [56]. Because we were unlikely to 
obtain meaningful data on heparin clearance rates in rats and because primate studies were 
not possible, we abandoned this study and instead investigated how the Stabilin-binding 
character of our heparin analogs influenced their route of elimination in vivo.  
 
Anti-Xa activity and elimination route in mice 
 BALB/c mice were used to investigate the bioactivity and elimination route of our four 
compounds. To confirm that the compounds were bioavailable by subcutaneous injection, 
four mice were injected with each compound (or with PBS as a control), and blood was 
collected by cardiac puncture after a 30-minute incubation. The samples were spun down to 
isolate plasma, and the anti-Xa activity of the PBS- and HS-injected mouse samples were 
compared using a chromogenic assay. The four compounds showed similar activity and did 
not exhibit a correlation between length and anti-Xa activity. This suggests that pure 
oligosaccharides ranging from a 6-mer to a 12-mer are equally bioavailable and confirms 
that they show anti-Xa activity in vivo, a common indication of anticoagulant activity.  
Having shown that our compounds exhibited anti-Xa activity in vivo, we questioned 
how their Stabilin-binding character would influence their clearance by the liver or by the 
kidneys. We expected that the 10-mer and 12-mer, which contain Stabilin-binding 
structures, would be present in the liver after a short incubation time, whereas the 6-mer and 
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8-mer (which are not Stabilin binding) would be cleared primarily by the kidneys and would 
be detectable in urine. 
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Figure 5.3. Factor Xa inhibition in mice. Male BALB/c mice (16-20 g) were injected subcutaneously 
with HS at 100 nmoles/kg. After 30 minutes, mice were sacrificed and blood was collected via cardiac 
puncture. Isolated plasma was tested for Xa activity using a chromogenic assay with plasma from 
PBS-injected mice as a control. n = 4 mice per compound, 3 assays per sample.  
 
 
   
 35S-labeled versions of the four compounds were synthesized and injected in mice 
intravenously. Radiolabeled unfractionated heparin and a 7-mer (an ultra-low-molecular-
weight heparin that showed no Stabilin binding) were used as controls. Livers and urine 
were collected after a ten-minute incubation and were processed for scintillation counting. 
The percentage of recovered radioactivity (in cpm) out of the amount injected was quantified 
for each compound. 
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Figure 5.4. Retention of oligosaccharides in mouse liver and urine. Equal amounts of 
35
S-labeled 
heparins were injected via the tail vein to male BALB/c mice. After a short incubation, the mice were 
bled out and the livers were processed for scintillation counting (A). 
35
S-radioactivity in the urine was 
also determined (B). Unfractionated heparin (UFH), which is known to be cleared by the liver, and a 
7-mer (ULMWH) that did not show Stabilin binding were used as controls. n = 4 mice.  
 
 
 The study found that the 7-mer control, 6-mer and 8-mer were retained at a very low 
level, whereas the 10-mer and 12-mer showed greater retention in the liver than UFH. In the 
urine, the 6-mer and 7-mer were present to a much higher extent than the other compounds. 
These data support the hypothesis that Stabilin-binding oligosaccharides are primarily 
cleared by the liver and that non-Stabilin-binding ones are cleared by the kidneys and 
excreted in urine. This information could be useful in the future design of heparins for 
patients with renal impairment and suggests different clinical applications for the four 
compounds designed in this study.  
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Conclusions 
 These studies present the first synthesis of structurally homogenous heparin 
oligosaccharides with anticoagulant activity. Four heparan sulfate constructs, a 6-, 8-, 10- 
and 12-mer, were prepared by sulfating the sugars concurrently with saccharide chain 
elongation.  As a result, C5-epimerase exhibited its irreversible reaction mode and IdoA 
residues were locked in place, allowing the formation of repeating IdoA2S-GlcNS6S regions.  
 When compared to an existing low-molecular-weight heparin, Lovenox, the 10-mer 
and 12-mer were more reversible by protamine in an in vitro assay. The 10-mer and 12-mer 
were also retained in the liver, not the kidneys, to a greater extent than the 6-mer and 8-mer, 
which is consistent with our data on Stabilin binding. Avoiding heparin kidney clearance 
would be highly advantageous for renally impaired patients and for elderly patients, who 
experience reduced clearance of drugs eliminated by the kidneys due to physiological 
changes in old age [160]. All four compounds exhibited similar anti-Xa activity in mice, 
suggesting that bioavailability does not change within this oligosaccharide size range.  
 Despite the passage of nearly a century since its discovery, the chemical structure of 
the drug heparin has gone largely unchanged. The first decades of its use saw the 
development of depolymerized low-molecular-weight heparins and later, the synthesis of the 
AT-binding pentasaccharide region by both chemical and enzymatic methods. After the 
development of Arixtra, innovations in the heparin field have primarily focused on extending 
the half-life of the drugs. This has been achieved by adding tags such as biotin and by 
replacing sulfo groups with less reactive methyl groups. Despite these advances, there has 
been no targeted development of heparin analogs that have specific biological functions or 
meet the needs of specific patient populations.   
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Breakthroughs in the field of heparan sulfate synthesis and in understanding 
heparan sulfate biochemistry have facilitated the production of heparan sulfate constructs 
that have desirable biological activities. We hope that these innovations will enable the 
development of new heparin drugs that better serve patients requiring anticoagulant 
therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER VI 
CONCLUSIONS 
 
Heparan sulfate is a ubiquitous carbohydrate that regulates many physiological 
events. A special highly-sulfated form of heparan sulfate, heparin, has been exploited for its 
anticoagulant activity and used as a drug for over 70 years. Due to the abundance of 
electronegative sulfo groups on the sugar backbone of heparin, it engages in both specific 
and nonspecific interactions with many proteins. A chemoenzymatic method was employed 
to prepare many heparan sulfate compounds having different sulfation patterns; in some 
cases, oligosaccharides of different lengths were also utilized.  
First, the substrate specificity of the Sulf-2 enzyme and its effect on HS-PF4 binding 
was examined. Sulf-2 removes sulfo groups from HS, and we hypothesized that treatment 
with Sulf-2 would affect binding between HS and platelet factor 4. Sulf-2 was previously 
shown to remove a 6-O-sulfo group from trisulfated disaccharides [101]; in addition, we 
found that 6-O-sulfo groups were removed from disaccharides carrying N- and 6-O-sulfation 
but not 2-O-sulfation. These studies were completed using HS polysaccharides prepared 
with a 35S-label at a specific sulfo group. By comparing Sulf-2-treated and untreated HS, we 
also confirmed that treatment with the Sulf-2 enzyme will reduce binding between HS and 
PF4 by approximately 10 to 20-fold but will not affect binding to antithrombin. 
The PF4 binding character of size-defined oligosaccharides was also examined. HS 
oligosaccharides having 15, 17, 19 and 21 sugar units were synthesized to investigate the 
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effect of size on the ratio of anti-IIa to anti-Xa activity. The 19-mer and 21-mer had 1:5 and 
1:2 anti-IIa/Xa ratios, respectively, and the 15-mer and 17-mer were too short to have anti-
IIa activity. All four oligosaccharides bound to PF4 in a dot blot assay; however, they bound 
to a much lower extent than unfractionated heparin. The anti-Xa activity of the 21-mer, 
which had the highest anti-IIa activity, was compared to an ultralow-molecular-weight 
heparin (7-mer) and full-length heparin. PF4 had no effect on the 7-mer and was able to fully 
neutralize the anti-Xa activity of full-length heparin; the 21-mer showed significantly reduced 
neutralization by PF4. Thus, Sulf-2 treatment and reduced length are proposed as methods 
to reduce binding between heparin and PF4. 
Stabilin-2, a scavenger receptor located on sinusoidal endothelial cells, was 
identified recently as a clearance receptor for heparins [81]. It had been determined that 
Arixtra (which is cleared by the kidneys) does not bind Stabilin-2, while unfractionated 
heparin (which is cleared primarily by the liver) does bind. We hypothesized that HS 
sulfation and length would control binding to Stabilin-2 and that binding to Stabilin-2 would 
result in liver clearance. First, by synthesizing HS polysaccharides and testing them for 
internalization by Stabilin-expressing cells, we found that Stabilin binding appeared to be 
somewhat charge-dependent but that the addition of 3-O-sulfation led to much greater 
internalization. This finding was confirmed by direct binding assays between the HS 
constructs and purified Stabilin ectodomains. Incubation of Stabilin-binding constructs with 
antithrombin in the cell internalization assay indicated that there is some overlap between 
the Stabilin and AT binding sites on HS.  
With the structural information gathered from the polysaccharide studies, a series of 
oligosaccharides were prepared that contained the Stabilin-binding motifs but varied in 
length. We found that a 10-mer was required for robust binding to Stabilin-1 and Stabilin-2, 
and that removing the 3-O-sulfation nearly eliminated the internalization of a 10-mer and 12-
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mer.  Additionally, we found that the 3-O-sulfated 10-mer was retained in the liver to the 
same extent as heparin after administration to mice, indicating that a Stabilin-binding LMWH 
should avoid clearance by the kidneys. This would be beneficial for kidney-impaired and 
elderly patients, and it would have a shorter half-life than small heparins like Arixtra.   
Later studies focused on the bioactivity of four new pure compounds that were 6-12 
sugars in length. All compounds contained an AT-binding domain and repeating IdoA2S-
GlcNS6S units, which are commonly found in heparin but not HS. The compounds had 
similar binding affinities for antithrombin in affinity co-electrophoresis assays. In anti-Xa 
activity assays, the activities of the 10-mer and 12-mer were more effectively reversed by 
protamine than Lovenox, a common LMWH, suggesting that a pure heparin compound 10-
12 sugars long could be more reversible that the low-molecular-weight mixtures that are 
currently available.  
In vivo studies in rats proved incapable of distinguishing the different half-lives of the 
drugs, but the subcutaneous bioavailability of the compounds was confirmed by 
administration to mice and anti-Xa testing. As anticipated after the cell-based assays, 
additional mouse experiments showed that the 10-mer and 12-mer were retained in the 
liver, not in urine, to a much higher extent than the 6-mer and 8-mer.  
When considering strategies for improved heparins, the research presented in this 
dissertation provides several pieces of new information that could be beneficial to the design 
of new anticoagulants. First, two methods are proposed to reduce binding to PF4 and 
potentially heparin-induced thrombocytopenia: removal of 6-O-sulfation by treatment with 
Sulf-2 and limiting the size of the oligosaccharide. In our studies, HS constructs up to a 21-
mer had reduced binding to PF4 compared to full-length heparin. Next, we demonstrated 
that binding to Stabilin receptors can be achieved with HS that is at least 10 sugars in length 
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and contains N-, 2-O-, 6-O- and especially 3-O-sulfation. This finding should allow the 
design of short heparins with either short half-lives and liver clearance or long half-lives and 
kidney clearance. In addition, HS constructs up to a 12-mer were found to be available by 
subcutaneous injection. While we did not investigate the maximum length for this 
administration route, this shows that pure synthetic compounds in the size range of LMWHs 
will not need to be given intravenously. We hope that these findings will be useful in the 
synthesis of new heparin drugs that are safe, effective and well suited for different patient 
populations.  
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